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Abstract 
Facing the upcoming application possibilities of genomic sequencing in human health research, to 
determine the appropriate ethical scope of genetic counselling for research participants becomes a 
most important challenge. In this thesis, an informed consent model for the disclosure of incidental 
findings in research using whole genome sequencing or whole exome sequencing will be presented. 
 
The design of an informed consent model is always based on a general informed consent theory. 
Thus, informed consent models can be defined as application of an ideal informed consent theory, 
containing general ethical principles, to a particular context. 
 
The aim of the thesis is to design and defend an inform model that determines the appropriate ethi-
cal scope of genetic counselling process for the disclosure of incidental findings –which I call the 
iterative feedback model due to the continuous informed consent process for the disclosure of inci-
dental findings between counsellor and individual research participant. For this purpose, informed 
consent theories will be analysed and adapted to the case of human health research using whole ge-
nome/exome sequencing. Furthermore, relevant values of research ethics and characteristics of ge-
nomic data will be taken into consideration. The iterative model of informed consent is based on the 
traditional and on the dynamic consent models to ensure understanding and autonomous choice by 
research subjects. 
 
Resumen 
Frente a las posibilidades inmediatas de aplicación de la secuenciación genómica en la investiga-
ción en salud humana, determinar  el alcance ético apropiado del asesoramiento genético (“counse-
lling”) de participantes se convierte en una cuestión de la mayor importancia. En esta tesis, se pre-
sentará un modelo de consentimiento informado para la divulgación de los hallazgos incidentales en 
la investigación que utiliza procedimientos de secuenciación del genoma completo o secuenciación 
de exoma completo.  
El diseño de un modelo de consentimiento informado se basa en la teoría general del proceso de 
consentimiento informado. Por lo tanto, los modelos de consentimiento informado pueden definirse 
como una aplicación de la teoría de consentimiento informado ideal, que incorpora principios éticos 
generales, en un contexto particular.  
El objetivo de la tesis es diseñar y defender un modelo de informe que determina el alcance ético 
apropiado del proceso de asesoramiento genético para la comunicación de hallazgos incidentales al 
cual  llamo “modelo iterativo” para resaltar la continuidad del proceso de consentimiento informado 
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entre el consejero y el participante de la investigación. Para ello, las teorías de consentimiento in-
formado serán  analizadas y adaptadas al caso de la investigación en salud humana con procedi-
mientos de secuenciación de genoma/exoma completo. Además, valores relevantes a la ética de la 
investigación y características de los datos genómicos serán tomados en consideración. El modelo 
iterativo de consentimiento informado se basa en los modelos de consentimiento informado tradi-
cional y dinámico, para asegurar la comprensión y la elección autónoma por parte de los sujetos de 
la investigación. 
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Chapter 1. Introduction 
 
1. General Introduction 
 
There is an ongoing discussion in the literature, legal and ethical committees world-wide addressing 
the disclosure of incidental findings in whole genome sequencing (WGS)/whole exome sequencing 
(WES) research. Facing the rapid acceleration of WGS/WES technology development and their 
practical implementation in research and clinical routine, there is an urgent need to develop and 
define ethical and legal standards for informed consent and disclosure of incidental findings. 
 
Even though the US national bioethics advisory commission (NBAC) favored the model not to 
return incidental research findings in 1999, several organizations and advisory commissions 
complemented guidelines suggested over time that research individuals should be offered to learn 
about incidental findings that can affect their health outcome (Wolf et al. 2012, Bradbury, 
McCormick and Robson 2014). Among others, the institutions that most recently developed specific 
recommendations for the report of incidental findings in the context of WGS/WES are the American 
College of Medical Genetics and Genomics (ACMG) and the US Presidential Commission for the 
study of bioethical issues in 2013. Moreover, topics like share of decision making between research 
providers and participants or the right to reject receipt of incidental findings are addressed in these 
guideline documents (Presidential Commission 2013).  
 
Informed consent is a major requirement in clinical research and applies to the setting of research 
studies involving humans and using WGS/WES procedures. In the course of history, informed con-
sent was more and more refined and adapted to specific settings, in particular to research studies. 
However, due to the broadened implementation of new technologies in clinical research, as 
WGS/WES, the informed consent requirement needs to be adapted to the technological challenges 
and specific ethical problems that arise in this context (Presidential Commission 2012).   
 
Especially in the new field of genetic counseling and whole genome data collection, it is always 
dealt with the delicate topic of racism, discrimination, and eugenics that showed us in recent history 
the possible consequences of missing autonomy. A first intuition that I will defend in this disserta-
tion is that the disclosure genetic data demands comprehensive counseling process prior to consent-
ing, as it is linked to very personal, predictive and determinative data. 
 
Several informed consent models have been developed to address the ethical needs in the setting of 
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clinical research with WGS/WES data and the return of research results. However, facing the prob-
lems that arise in their concepts and practical application, there is still space for improvement, espe-
cially with regard to the information process and guided communication transmission of research 
results. Ideally, a consent model has to be compatible with various aims in research and public 
health and with individual well-being which can be sometimes discordant.  
 
The objective of the thesis, which will be developed in full detail in Chapter 4, is to develop and 
describe an informed consent model –“the iterative feedback model”– for potential participants in 
human health research studies using whole genome sequencing (WGS)/whole exome sequencing 
(WES) procedures, and for the disclosure of incidental findings after the enrollment in a research 
study. I will defend a model that supports and puts emphasis on the communicative process with the 
research participant, a crucial component of the informed consent process. Even though there will 
be objections discussed at the end of chapter 4, the model tries to outpace defects of other models 
that will be described in the course of chapter 4. The hypothesis is that the iterative feedback model 
fits better than the alternative models the ethical framework containing generally accepted ethical 
principles of research ethics and the specific characteristics of WGS/WES data. 
 
Guidelines by the US Presidential Commission for the study of biomedical issues (2013), the paper 
“A Framework for Analyzing the Ethics of Disclosing Genetic Research Findings” by Eckstein et al. 
(2014), as well as the paper “Models of Consent to Return of Incidental Findings in Genomic Re-
search” by Appelbaum et al. (2014) are selected literature for this work. The US Presidential Com-
mission for the study of bioethical issues is an advisory panel of physicians, scientists, ethicists, 
lawyers, engineers, and theologians that advises the president on bioethical issues in the fields of 
biomedicine, science and technology (Presidential Commission 2012&2013). In this thesis, it will 
be referred to the Commission’s guidelines in various paragraphs in view of the Commission’s 
strong lead on guidelines addressing the return of findings and ethical issues arising as a result of 
the rapid progress of WGS/WES technologies. In particular, the guideline document “Anticipate 
and Communicate. Ethical Management of Incidental and Secondary Findings in the Clinical, Re-
search, and Direct-to-Consumer Context” (2013) will contribute to the clarification of the terminol-
ogy for research findings. In this regard, the paper “A Framework for Analyzing the Ethics of Dis-
closing Genetic Research Findings” by Eckstein et al. (2014) offers another approach for the classi-
fication of research findings and explains which criteria findings must meet in order to be revealed 
to research subjects. Eventually, the paper “Models of Consent to Return of Incidental Findings in 
Genomic Research” by Appelbaum et al. (2014) outlines informed consent models for the feedback 
of incidental findings which are commonly found in the literature. The authors give an ethical eval-
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uation of the models by using the criterion “researchers’ ethical obligation” and point out ad-
vantages and disadvantages of the models regarding the criterion of “practicality”. I will incorporate 
this approach by applying the ethical principles that will be mapped out in the theoretical frame-
work to these informed consent models.  
 
 2. General and specific aims 
 
The general aim of the thesis is to develop an ethical framework for an informed consent model for 
the disclosure of incidental findings in the setting of whole genome sequencing (WGS)/whole 
exome sequencing (WES) research with human research individuals.  
In the course of the thesis, several informed consent models will be analyzed and furthermore 
challenged by applying ethical principles. As mentioned, it will be taken into account that a consent 
model has to be compatible with principles and values in research and public health, as well as with 
the research individual’s well-being and rights. Since a consent model never fits all of the proposed 
interests, the thesis’ aim is to carefully weigh every suggested reasonable position. The ethical 
analysis of the informed consent models is supposed to guide the reader towards the “iterative 
feedback model”, a model incorporating already existing consent theories by simultaneously 
covering crucial ethically demanded principles. Thus, the ethical analysis demonstrates why the 
“iterative model” fits best the demands of overarching ethical principles among the analyzed 
informed consent models for research studies using WGS/WES procedures. Another important aim 
of the thesis is to point out the strengths and weaknesses of the “iterative feedback model”. 
 
After having outlined the general aim and idea of the thesis, the more specific aims as well as the 
more detailed proceeding will be presented.  
The first specific aim of Chapter 2 and 3 is to picture biological theories, technology, statistical 
evaluation of genetic tests and the history of informed consent theories, as well as legal aspects of 
informed consent and the disclosure of research findings in the United States. This background 
knowledge should help the reader to understand why ethical issues arise when considering the case 
of research studies involving human subjects and using WGS/WES procedures. 
Subsequently, chapter 4 addresses the development of an ethical framework for the disclosure of 
incidental findings in research studies using WGS/WES procedures by evaluating ethical theories 
for informed consent, by highlighting crucial ethical principles in this context, and by evaluating the 
particular importance of each principle. Furthermore, a paragraph will be dedicated to outline the 
characteristics of WGS/WES data and the return of findings to research participants. This should be 
considered a supportive tool to point out the specificity of WGS/WES research and to design of the 
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iterative feedback model. Also, introducing a genome wide association study (the rare diseases 
genomes project) as case is supposed to help the understanding of ethical issues and questions in 
this context.  
 
Moreover, the theoretical framework of chapter 4 tries to give valuable definitions on terms 
connected to the ethical analysis of research studies using WGS/WES technologies. One section is 
fully dedicated to clarify and re-define the terminology of research findings, incidental findings, 
secondary findings etc. Also, one of the aims is to clearly set the conditions when findings should 
be disclosed to participant regarding the vast amount of data generated by WGS/WES.  
 
Taking into account the developed ethical and terminological framework, current informed consent 
theories applied to the context of research studies using WGS/WES procedures and the disclosure 
of incidental findings will be introduced and evaluated. Advantages and disadvantages of each 
model will be outlined. Facing the main benefits and problems after the evaluation, an alternative 
model will be presented – “the iterative model” - based on the strengths and weaknesses worked out 
before. In the further course of the thesis, the “counselling process” will be described, a crucial 
characteristic of the iterative feedback model. 
Finally, the main challenges arising in the context of the implementation of this model will be 
presented and discussed.  
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Chapter 2: Scientific background of genetics and whole genome/whole exome 
sequencing  
 
1. Introduction 
 
The objective of this chapter is to introduce the main terminology of biological processes related to 
genetics. I will introduce several definitions on genetics in general and DNA formation, translation 
and transcription in particular. Moreover, an essential paragraph will be dedicated to define 
mutations and to classify them – with regard to genetic tests and the detection of genetic aberrations.  
 
A crucial paragraph will describe technical reliability of genetic tests and what to consider when 
statistical risks derived from whole populations or cohorts are transferred to single individuals.  
 
Based on the overview on biological processes and genetic tests, the chapter also depicts how 
sequencing technologies have evolved and how they could develop in the near future. Furthermore, 
this chapter addresses the application range of genetic sequencing and gives a short outlook on 
bioinformatics supporting the implementation of whole genome/whole exome sequencing in clinical 
routine and research. 
 
2. Genetics 
 
“Genetics” is a subfield of biology addressing the transfer of hereditary dispositions to next 
generations of particular cells or to an organism. In contrast, “epigenetics” investigates the activity 
of such hereditary dispositions in different tissues, as well as mechanisms controlling those 
activities. The “genotype” is the totality of genetic dispositions regarding a whole organism, while 
the “phenotype” refers to characteristics that appear in an organism, including anatomical, 
physiological, biochemical, epigenetic and (in complex organisms) psychological characteristics 
during its life-span (Deutscher Ethikrat 2013:8). 
 
In the following sections, the composition of the genetic code, as well as its translation into proteins 
which play a major role in the physiology and biochemical processes of an organism will be 
described. The basic aspects of the genome, its transcription into RNA and its translation into 
proteins, is outlined in Figure 1.  
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Figure 1: “The structure of DNA”, Source:  Presidential Commission (2012:17). 
 
2.1. Components building the genetic code  
 
DNA is a double stranded nucleic acid molecule in an alpha-double helix consisting of two anti-
parallel nucleotide strands. DNA is composed of four different nucleotides which repetitively build 
up the genetic code (Murken et al. 2006:2, Figure 1: “The structure of DNA”).  
 
There is a general distinction between nucleotide acids: desoxyribonucleotide acid (DNA) and 
ribonucleotide acid (RNA). Both types of nucleotide acids are polymers of nucleotides that are 
polymerized by pyrophosphate segregation of nucleoside tri-phosphates. Each nucleoside mono-
phosphate consists of an organic base, sugar and phosphoric acid. Those highly energetic nucleoside 
tri-phosphates build the basis for the synthesis of nucleotide acids, namely Adenine (A), Guanine 
(G), Cytosine (C) and Thymine (T). The nucleotides are complementary, binding to each other via 
the formation of hydrogen bonds: Adenine is complementary to Guanine, whereas Cytosine pairs 
off Thymine in DNA and with Uracil in RNA. The sugar used for DNA synthesis is pentose 
2’desoxyribose, while RNA is made of ribose. Furthermore, the base Thymine is replaced by 
Uracile (U) in RNA (Lister Hill National Center for Biomedical Communications 2015:9). 
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The 3’-OH-group of the sugar molecule and the 5’ phosphate acid group indicate a “direction” in 
the DNA molecule. The alpha-helix is stabilized by intermolecular forces (bonds between the 
complementary bases of the anti-parallel helix), and intramolecular forces (hydrogen bonds between 
helices, and so called stacking-interactions. In contrast, RNA is a single stranded molecule and can 
build intramolecular helical structures (Murken et al. 2006:1-6).  
                           
Figure 2: “The components of DNA”, Source: Lister Hill National Center for Biomedical Communications (2015:10) 
 
2.2. The human genome  
 
DNA is the carrier of genetic information. Genes are DNA sections that usually code for a particular 
gene product (RNA, protein).  
 
DNA of eukaryotes is arranged in a complex of DNA and histones and non-histone-proteins, which 
is called chromatin. Humans have 23 chromosomes, each consisting of two chromatid strands, 
either in a haploid (gamete and spermatozoon), or in a diploid chromosome set (other somatic cells). 
Segments of DNA are “genes” coding for proteins that can be translated and transcribed and 
regulate body functions (Harden 2010). During the “interphase” of the cell cycle, chromosomes are 
uncoiled. Thus, microscopic pictures showing the characteristic shape of chromosomes are taken 
during the “metaphase” (Murken et al. 2006:9).  
The sequence of bases composes the genetic code. Each amino acid is coded by a triplet of base 
pairs. This code is degenerated, meaning that there are more coding possibilities than necessary and 
most of the amino acids are coded by more than one particular composition of the triplet. The code 
is universal in all living beings (and viruses), comma free and non-overlapping. The AUG-triplet 
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generally serves as start-codon, coding for the amino acid Methionine (Murken et al. 2006:8-9). 
 
The biggest amount of DNA is located in the nucleus of a cell. In addition, there is DNA stored in 
mitochondria which are located in the cytoplasm (Murken et al. 2006:9-10). 
  
                                             
Figure 3: “The central dogma of molecular biology: DNA codes for proteins”  
Source: National Institutes of Health (2015). 
 
The human genome comprises 3 billion base pairs, although only 1.1% of the DNA contained in 
cells can be considered as coding regions (Lister Hill National Center for Biomedical 
Communications 2015: 13). There are about 25.000 genes coding for proteins. Since coding mRNA 
and proteins are further modified by posttranscriptional and posttranslational mechanisms, each 
gene can code for various different proteins. As a result the number of proteins found in the cell 
exceeds the number of genes (Murken et al. 2006: 12).  Genes are composed of coding regions 
(“exons”, ca. 1.1%) interrupted by non-coding regions (“introns”, ca. 24% of the genome). The 
remaining 75% of DNA consists of “intergenic” DNA – non-coding DNA between the transcribed 
units (MeSH Database Definitions 2015). The function of these non-coding sequences is currently 
intensively studied as there is a huge number of RNA molecules which are not involved in protein 
synthesis. The ENCODE project (Encyclopedia of DNA elements) investigating all functional 
elements of the human genome, suggests that at least 80 percent of the non-coding DNA (e.g. 
microRNAs, siRNAs, snRNAs) plays an essential role in the system of epigenetic gene regulation 
(Ecker et al. 2012, The ENCODE Project Consortium 2012). 
Main mechanisms of epigenetics are the modification of histones which wrap the DNA molecule. 
Likewise, gene products, as RNA and other proteins, can influence the reading process of DNA. In 
this way, epigenetic modifications determine when and where in a cell genes are expressed. 
Epigenetic modifications can be acquired, e.g. due to psychological stress, or environmental 
modifications, which can last for variable time periods. Some of these can be inherited, others are 
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short term modifications, regulating for instance the amount of gene products (transcription factors, 
repression factors), metabolism products, or hormones as needed for the cellular function in a given 
setting (Deutscher Ethikrat 2013: 11-13). 
 
Introns and exons are transcribed into messenger RNA (mRNA) (which will be explained in more 
detail in the following paragraph, compare also Figure 2 “The central dogma of molecular biology”). 
However, in a further step the splicing apparatus removes the introns from mRNA implying that 
only exons are translated into the end products – proteins. The so called “promoter regions” regulate 
the transcription process by giving the start signal via characteristic sequences as TATA or CAAT. 
“Regulatory sequences”, which are located near the genes, have the ability to bind proteins involved 
in the transcription process and interact with the promoter region and the RNA-polymerase. 
Eventually, “spacer sequences” are responsible for the position of regulatory sequences, and thus, 
for their further interaction with the promoter regions (Murken et al 2006:11-15).  
 
The human genome also exhibits repetitive sequences. Among these sequences, most of the regions 
still remain without or with unknown function (Murken et al. 2006:12). 
 
2.2.1. Replication of DNA 
 
During each cell division, genetic information is transmitted to the daughter cells. In order to divide, 
a cell must duplicate its genetic information, a process called replication. Replication takes place 
during the “S-phase” of the cell cycle and can be described as a “semi-conservative” process: the 
DNA double helix is uncoiled and both strands provide a template for the formation of new DNA 
strands. Hence, the chromatid contained in each chromosome is duplicated into two chromatids 
(Lister Hill National Center for Biomedical Communications 2015:29, Figure 4: “Mitosis and 
meiosis”) 
 
The division of body cells is depicted on the right. During meiosis, DNA replicates and is 
transferred to the daughter cells. In contrast to mitosis, meiosis (the cell division creating egg and 
sperm cells) is a two-step process that reduces the number of chromosomes by half (as only 23 
chromosomes are inherited from each mother and father). 
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Figure 4: “Mitosis and meiosis”, Source: Lister Hill National Center for Biomedical Communication (2015:29) 
 
 
2.2.2. Transcription  
 
The “translation” of genetic information into proteins is initiated by the transcription process. 
During this process, necessary components for the translation into proteins are synthesized, namely 
rRNA of the ribosomes, transportation units for the amino acids (tRNA molecules), and mRNA 
coding for proteins. The transcription is carried out by RNA-polymerases and takes place in the 
nucleus of eukaryotic cells (Lister Hill National Center for Biomedical Communications 2015:24). 
The reading process of DNA is carried out only at one stand of the double helix, the so called 
“coding strand”, from the 3’ to the 5’ end. The read out sequence is controlled by promoter 
sequences, each corresponding to a particular gene. The promoter is the starting point where 
transcription begins and where it is regulated. In contrast to prokaryotic RNA-polymerases, 
eukaryotic RNA-Polymerases are not able to initiate the transcription process by themselves. So 
called “transcription factors” start the transcription process by accumulating at the promoter sites. 
Eventually, the RNA-polymerase is phosphorylated which triggers its release from the initiation 
complex and starts the mRNA synthesis. The transcription process is stopped by the signal of 
“palindromic nucleotide sequence” of the DNA. Such “palindromic base pairs” lead to a loop in the 
RNA structure and signal the termination of mRNA synthesis (Murken 2006:21-22).  
 
2.2.3. Posttranscriptional modification of mRNA  
 
In contrast to DNA-polymerases, RNA-polymerases do not show proofreading activity due to the 
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vast amount of mRNA transcribed and released to the cytoplasm, and due to a high tolerance for 
single non-functional proteins. One of the most important posttranscriptional processes to mention 
is the splicing mechanism. In a complex splicing and synthesis process of gene products, 
transcribed introns are removed (spliced). The so called “spliceosome” tags intron-exon transitions 
and splices the mRNA sequence at the indicated loci. Furthermore, the nucleotide sequences of 
exons are merged and transported to the cytoplasm (Murken et al. 2006:24). Alternative splicing 
refers to the possibility of keeping facultative introns in the “mature” mRNA sequence which is 
transported to the ribosomes. Hence, alternative splicing –the different combination possibilities of 
introns and exons– lead to different gene products. In consequence, the number of functionally 
different gene products clearly exceeds the number of genes contained in the DNA sequence 
(Murken et al. 2006:22-25).  
 
2.2.4. Transcriptional regulation  
 
Eukaryotes regulate genes individually. Gen regulatory proteins can bind to particular DNA regions 
tagged by binding motives, such as the “helix-turn-helix”, “homeodomains”, or “TATA-boxes”. 
These regions can interact with transcription factors and the RNA-polymerase II and thus control 
the transcription mechanism (Murken 2006:25). Moreover, specific proteins that bind at these 
regions are able to either enhance or to silence genes by controlling the RNA-polymerase activity. 
Alternative splicing can serve as a regulatory mechanism, regarding the selectivity of genetic 
information that is transcribed. Likewise, the methylation of cytosine rests of CpG (Cytosine-
Guanine) islands influences the gene expression. Increased methylation goes hand in hand with a 
reduced gene expression of the gene behind the methylated region (Murken et al. 2006:26).  
 
2.2.5. Translation  
 
The translation of mRNA into proteins is carried out at the ribosomes whose subunits are located in 
the cytoplasm. The translational mechanism is subdivided into initiation, elongation and termination. 
In order to initiate translation, an initiation complex is formed, consisting of mRNA, initiation 
proteins, the small ribosomal subunit, and initiator tRNA (Lister Hill National Center for 
Biomedical Communications 2015:24). 
During the elongation process, mRNA is read out in triplets from the 5’ to the 3’ end. tRNA 
molecules carry amino acids which bind to free triplets of the mRNA. Meanwhile, elongation 
factors support the binding process. The elongation mechanism is continued until the stop codon is 
reached (there is no charged tRNA molecule corresponding to the stop codon). Eventually, binding 
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“release factors” trigger the liberation of the synthesized protein and the decomposition of the 
ribosome to its subunits (Murken et al. 2006:30).  
 
2.2.6. Posttranslational modification of proteins  
 
The functionality of proteins can be achieved directly after their synthesis. Nonetheless, it is also 
possible that full functionality needs further modification.  
For instance, the activation of proteins can be regulated by “exo-“ or “endopeptidases”, or by 
adding functional groups such as carbohydrates. Furthermore, a common mechanism to activate 
proteins is phosphorylation executed by protein kinases, as well as the acetylation or methylation of 
proteins (Murken et al. 2006:32-34). 
 
2.3. Mutations 
 
The information of the DNA is subject to permanent changes, so called “mutations”. Single bases, 
as well as whole sequences can be exchanged, deleted, duplicated, or inserted at different genetic 
loci through the mutation process:  
The majority of genetic diversity is based on single nucleotide polymorphisms (SNPs). Two related 
human genomes differ in every thousandth base pair on average. Approximately 60.000 SNPs are 
located in coding regions of the genome. DNA-copy variants, as deletions and duplications of DNA 
sequences, can lead to modifications in the genome. Furthermore, differences in the repetition of 
sequences contribute to the variability of the genome (Murken et al. 2006:14-15).  
 
In the context of evolution, mutations remain if they improve surviving abilities for the organism in 
a given environmental setting. Mutations that imply a disadvantage for the organism underlay 
negative selection and cannot be established over several generations.  
 
Mutations of genes lead to the formation of so called “alleles”, different variants of a certain gene, 
which are located at the same genetic locus of homologue chromosomes. There are many different 
alleles found in a population. However, an individual has only 2 alleles due to its diploid 
chromosome set. In case of identical alleles, the gene is called “homozygote”, whereas two different 
alleles are “heterozygote” by definition. 
Genetic variability develops due to random combinations of different alleles inherited from the 
parents. Thus, a mutation is any genetic aberration in the DNA sequence which changes the 
sequence from a normal allele prevalent in the population to an abnormal or rare variant. A 
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“polymorphism” is a variation of DNA sequence which is common in the population. The threshold 
set between a mutation and a polymorphism refers to an incidence of 1% or more in the population. 
If the frequency of a genetic aberration is lower than this cut-off point, the altered allele is regarded 
as a mutation (Twyman 2003).  
There are also other mechanisms, as epigenetic modifications, contributing to the phenotypic and 
genotypic individuality of organisms (Murken et al. 2006:14-15).  
 
Mutations can either be inherited (so called “germ line mutations”) or acquired (“somatic 
mutations”), which can be spontaneous, i.e. random, or a result of environmental mutagens, e.g. in 
cigarette smoke. In contrast to germ line mutations, somatic mutations are located in a limited 
number of somatic cells and do not show inheritance patterns (Lister Hill National Center for 
Biomedical Communications 2015:39). An example for a germ line mutation in breast cancer 
patients are genetic modifications of the BRCA1/2 genes, whereas a common somatic mutation in 
cancer affects the p52 gene. Most of the observed mutations are the result of events, such as DNA-
replication errors, or recombination errors (cross-over-errors during meiosis). Furthermore, other 
causes of mutations, as the effect of chemicals, or radiation induced modification of nucleotide 
acids have been extensively studied (Murken et al. 2006:58; 63).  
 
Not all genetic modifications, as already explained, cause disadvantages for an individual. However, 
just a small percentage of mutations have a positive effect leading to a better adaptation to the living 
conditions of an organism. Moreover, some genetic aberrations alter a gene’s DNA sequence but do 
not change the function of the protein coded by the gene. Additionally, potentially harmful gene 
mutations are often repaired by enzymes before the gene is expressed and an altered protein made 
(Lister Hill National Center for Biomedical Communications 2015:45).  Each cell has pathways 
through which DNA can be repaired and which protect the body from many genetic alterations 
caused by defective transcription or translation. 
 
The human genetic code is able to bear a large number of mutations without effects on health, since 
many pathways are protected by “alternative pathways”, achieving the same functionality with 
different molecular interactions. This can complicate diagnosing genetic conditions (the correlation 
of genetic aberrations with phenotypic changes) difficult. For instance, there can be a lack of clarity 
if a mutation is directly involved in the development of an unfavorable clinical condition; these 
genetic changes are called “variants of unknown significance (VOUS)”. VOUS often occur in the 
context of mutations at genetic loci which are not located in the suspected disease-related genes 
(Lister Hill National Center for Biomedical Communications 2015: 45). Anticipating the case study 
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(the “rare diseases genomes project”) that will be introduced in chapter four, in rare diseases there is 
frequently a lack of evidence for disease-causing variants due to limited data availability. 
  
2.3.1. Classification of Mutations  
 
Mutations can be classified into “genome mutations” (a changed number of chromosomes), 
“chromosome mutations” (aberrations of a huge part of the chromosome), and “gene mutations” 
(single aberrations of one or more nucleotides in a particular chromosome).  
Regarding genome mutations, a change in the number of chromosomes is subsumed under the term 
“aneuploidy”. Deletions, insertions, duplications of chromosomal areas, translocations, and 
inversions are possible mutational aberrations of chromosomes. Gene mutations include point 
mutations as substitutions, deletions and insertions of single nucleotides. Furthermore, mutations 
can consist of large-scale deletions and insertions of several kilo-bases or mega-bases (Murken et al. 
2006:42-43).  
 
Mutations are distinguished according to the locus of the mutation in the gene: mutations in the 
coding region (“silent mutations”, “missense mutations”, “nonsense mutations”), “frameshift 
mutations”, mutations in the promoter, in the splicing region or mutations of polyadenylated regions 
and of the Cap-site (Lister Hill National Center for Biomedical Communications 2015:43-44).  
Silent mutations code for the same amino acid (no protein change), missense mutations cause an 
amino acid change, and nonsense-mutations code for a stop-codon. Mutations causing a shift of the 
read out bases via a deletion or an insertion in the coding region of a gene are called frameshift 
mutations. If single nucleotides are mutated in the promoter region (promoter mutation), the 
expression of the gene is either up or down regulated. Furthermore, there are certain sequence 
motives in transition regions of exons and introns which are needed to initiate the splicing 
mechanisms. Mutations in those motives can hamper or change the splicing process. Likewise, 
polyadenylation of mRNA is necessary for the export of mRNA from the nucleus to the cytoplasm. 
Mutations of the polyadenylated regions can lead to less mRNA transportation or even stop the 
export completely (Murken et al. 2006:49).  
 
2.4. Diagnostic, prognostic and predictive genetic analysis 
 
Number and microscopic structure of the chromosomes, the sequence of the DNA, or the sequence 
of genetic products, as RNA, can be investigated via a genetic analysis. Thus, the genetic analysis 
can comprehend the analysis of single genetic loci or genome wide screening for genetic aberrations. 
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In contrast to other laboratory tests, a genetic analysis reveals a sequence of nucleotides (Lister Hill 
National Center of Biomedical Communications 2015:117). Hence, determining the amount of the 
DNA molecule is not within the scope of a genetic analysis.  
The result of a genetic analysis only shows clinical significance if the genetic variation implies a 
changed phenotype. Without the correlation between phenotype and genotype, genetic analysis 
cannot be used in terms of a clinical examination.  
In a clinical context, genetic analysis is used to diagnose germ line or acquired genetic aberrations 
that cause or can cause pathogenicity. For instance, cancer cells show acquired mutations in either 
oncogenes or tumor suppressor genes which can be revealed by a genetic analysis. This analysis can 
give predictive (e.g. therapeutic response) and/or prognostic (survival probability) information 
about the course of the disease or adequate therapeutic options. In contrast, predictive genetic 
diagnostics cannot be correlated to a yet visible phenotype, as disease or as functional impairments. 
The test aims for the prediction of future phenotypic changes, e.g. disease, by indicating a 
probability for future phenotypic alteration (Deutscher Ethikrat 2013:13-14). 
 
2.4.1. Effects of genetic dispositions on health and life  
 
Genes play an important role in organisms regulating physiological and biochemical functions 
which depend on the frequency of reading out genes and translating them into RNA products.  
Furthermore, an organism always keeps certain equilibria of physiological and biochemical 
processes depending on sex, age, nutrition, life style and other external conditions. In this regard, 
the mere coexistence of genetic variants (genotype) and a phenotypic characteristic of an individual 
can be considered coincidental. Statistical validation associates a genetic variant with phenotypic 
characteristics by studying whole populations. However, molecular or cell biological evidence is 
needed to confirm a cause-effect relation between genetic variant and phenotypic characteristic 
(Deutscher Ethikrat 2013:14).  
 
In some cases, a single aberration in the genotype can trigger a change in phenotypic characteristics, 
especially at the time when the functional impairment is due to a defect of a protein coded by the 
gene. For instance, carriers of a mutation in BRCA1/2 genes show defects in BRCA1/2 proteins 
which are essential to prevent breast and ovarian cancer due to their participation in a pathway that 
mediates error-free repair of DNA double strand breaks by homologous recombination (Friedenson, 
2007).  
 A mutation localized in a single gene and correlated with a high risk of disease development, 
disabilities or developmental disorders, is called a “monogenic” cause of disease. Such mutations 
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can be results of different patterns of inheritance (recessive or dominant) (Deutscher Ethikrat 
2013:19-20).  
 
In contrast to monogenetic causes, multi-factorial diseases are caused by more than one external 
factor (environmental conditions, nutrition, life style, side effects of medication) and/or genetic 
dispositions. For instance, arteriosclerosis, heart attacks, obesity, or diabetes type II can be 
considered multi-factorially caused diseases. These diseases are associated with complex genetic 
constellations and an even more complex phenotype. Therefore, it is difficult to extrapolate a clear 
cause-effect mechanism associating genetic dispositions and phenotypic characteristics. Since the 
development of a disease is constituted by genetic, epigenetic and environmental factors, it is more 
appropriate to call the corresponding genetic variants polymorphisms instead of (pathogenic) 
mutations (Lister Hill National Commission for Biomedical Communications 2015:68-69).  
 
Chromosomal aberrations can cause disorders which can lead to massive damage, even in the 
prenatal fetus. The range of chromosomal disorders comprises lethal disorders at an early 
embryonic stage (e.g. autosomal monosomies, polysomies etc.), as well as aneuploidies or 
hyperdiploidies (e.g. trisomy 21) which do not strongly affect the viability of a fetus (Deutscher 
Ethikrat 2013:25-27). 
 
In consideration of genetic aberrations and their effects on the phenotype of an organism, it has 
been presented how genetic dispositions and external factors can affect an individuals’ health. 
Moreover, it has been stated how genetic tests can be used to diagnose or to predict a current or 
future health state. In the next section, the focus will be on the development and state of the art 
knowledge of genetic diagnostics and research technologies.  
 
3. State of the art knowledge: genetic diagnostics and research technologies 
 
High-throughput sequencing technologies have revolutionized genome analysis and consequently 
genetic diagnostics possibilities, not least because of the enormous technological shift during the 
last decade and due to dramatically dropping costs per sequenced base of raw sequence 
(Niedringhaus et al. 2011). Also, advances in bioinformatics go hand in hand with the development 
of sequencing technologies (Deutscher Ethikrat 2013:32). Efforts in sequencing cost reduction and 
genome wide analysis paved the way for groundbreaking insights into complex diseases. This 
development supports research on genetically caused diseases which requires a huge amount of 
genomic data in order to investigate genotype-phenotype relationships clinical and therapeutic 
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research could take advantage of (Deutscher Ethikrar 2013:32-34).  
 
Figure 5a/b shows the significant cost reduction in sequencing technologies depicting the “cost per 
megabase of DNA sequencing” as well as the “cost per genome” (National Human Genome 
Research Institute 2015). 
 
 
 
Figure 5a: “Costs per raw Megabase of DNA sequence” Figure 5b: “Cost per Genome” 
Source: National Human Genome Research Institute (2015) 
 
Regarding the two graphs, the costs are accounted for: laboratory, administration, sequencing 
instruments and related large equipment, information management systems, shotgun library 
construction. Not reflected costs are: quality assessment/control for sequencing projects, 
development of bioinformatics, informatics equipment, data analysis (e.g. indentifying variants, 
interpretation of results). 
 
The graphs do not only depict the quickly dropping sequencing costs, but also show curves of 
Moore's law – a hypothetical curve (depicted on a logarithmic scale) which describes long-term 
trends in the computer hardware industry that amounts to the doubling of “compute power” every 
two years. Technologies that are able to maintain the innovation rate of Moore's Law are considered 
outstanding developments (National Human Genome Research Institute 2015).  
 
In 2008, the implementation of so called “second generation sequencing” or “next generation 
sequencing” (NGS) technologies, high-throughput technologies led by Illumina, Roche and Life 
Technologies, was launched. Sanger-based sequencing (dideoxy chain termination sequencing) was 
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then replaced by more innovative NGS methods which have the capacity to sequence a large 
quantity of DNA fragments simultaneously. This resulted in a tremendous break-through in 
sequencing cost and time reduction (National Institute of Human Genome Research 2015). Due to 
the introduction of next generation sequencing technologies, it will be possible to sequence a whole 
human genome for approximately 1.000 US-Dollar in the next 5-10 years (Deutscher Ethikrat 
2013:33; Mardis 2011). Regarding the rapidly dropping price of whole genome sequencing (WGS), 
it is rather convenient to sequence whole genomes instead of performing discrete genetic tests 
(Presidential Commission 2012:30). Sequencing the coding exons (whole exome sequencing, WES), 
composing the “exome” (the exome only makes up 1% of the whole genome with approximately 
4.6 billion base pairs), needs less data retention while showing higher data quality. However, it 
should be taken into consideration that there still remains the difficulty of data interpretation. For 
instance, raw sequences need to be evaluated; data has to be harmonized consistently and compared 
with references, and unknown variants have to be identified. Eventually, the “1000 dollar genome” 
converts into a “100.000 dollar interpretome” (Perkel 2013).  Although advanced interpretation and 
reporting software is undergoing rapid development, Perkel (2013) claims that from a clinical point 
of view, automated steps are not sufficient to identify variants underlying special phenotypes or 
human diseases. 
 
Nevertheless, the price per sequenced genome strongly depends on the degree of capacity utilization. 
Furthermore, data interpretation tools are developing and improving, just as data bases containing 
genome-phenotype-profiles grow. Hence, it can be assumed that the development of new algorithms 
for data analysis is just a matter of time (Deutscher Ethikrat 2013:33).  
 
3.1. From First to Next Generation Sequencing 
 
DNA sequencing was pioneered by Sanger and Coulson who developed the chain termination 
method in 1975 together with Maxam and Gilbert who came up with a method of chemical DNA 
modification in 1976-1977. In 1977, Sanger sequenced the first genome of the bacteriophage phi X 
174, which contains 5375 base pairs in length (Niedringhaus et al. 2011). In the mid 1980s semi-
automated DNA platforms were developed, followed up by more cost-effective nucleases, 
polymerases, more rapid template preparation etc. (Slatko et al. 2011).  
 
Two principles of genetic analysis dominate genetic sequencing in human beings: the hybridization 
of oligo-nucleotides and the polymerase-chain-reaction (PCR) (Deutscher Ethikrat 2013:30).  
Since the 1990s, the DNA sequencing market has been almost exclusively dominated by capillary-
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based, semi-automated machines based on the Sanger method (primary offered by Applied 
Biosystems, then integrated into Life Technologies and Beckman Coulter) (Niedringhaus et al. 
2011). Regarding this method, DNA can be prepared in two ways. For shotgun de novo sequencing, 
randomly fragmented DNA is cloned and subsequently transferred into Escherichia coli (cf. Figure 
6a). “Shotgun” means to enzymatically fragment DNA and sequence the fragmented strands 
(Schlebusch and Illing 2012). For targeted re-sequencing, a PCR is performed with primers 
delineating the target gene sections. Consequently, either many clonal copies of a single plasmid in 
a bacterial colony or PCR amplicons in a single reaction volume can be picked as an amplified 
template. The sequencing reaction takes place in a “cycle sequencing” reaction, in which cycles of 
template denaturation, primer annealing and primer extension are performed. Each round of primer 
extension can be stochastically stopped by the integration of fluorescently labeled 
dideoxynucleotides (ddNTPs). As a result, the label of the terminating ddNTP of DNA fragments 
matches the nucleotide identity of the final position (Shendure and Hannlee 2008). When the 
extended DNA fragments are subsequently ordered according to their lengths, the sequence can be 
read out, assuming that every length appears at least once due to the statistical break off at any 
possible position in the PCR extension phase. Thus, the labeled nucleotides and the order of their 
sequence can be made visible, up to sequences of around 1.000 base pairs.  
 
Since the 1980s, the Sanger method got more and more elaborated not only by the development of 
an optical detection of ddNTPs labeled fragments, but also by the introduction of capillary 
electrophoresis to read out the detected sequences, which led to a fully automated sequencing 
system. After further improvements in the 2000s, Sanger sequencing costs approximately 0.50 
dollar per kilobase. However, there are NGS methods which enable sequencing costs per megabase 
under 0.1 dollars (Shendure and Hanlee, 2008).  
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Figure 6: “First versus Next Generation Sequencing”, Source: Shendure and Hanlee (2008). 
(a) “With high-throughput shotgun Sanger sequencing, DNA is fragmented, cloned to a plasmid vector used to 
transform E.coli. [...] DNA sequence is read out via capillary electrophoresis.”  
(b) “In shotgun sequencing with cyclic-array methods, common adaptors are ligated to fragmented genomic DNA. 
[...] Imaging-based detection of fluorescent labels is used to acquire sequencing data on all features in parallel. 
Successive iterations of enzymatic interrogation and imaging are used to build up a contiguous sequencing 
read for each array feature.” 
 
In the context of the “Human Genome Project” which started in 1990 (Collins 1999), the first 
composite human genome was sequenced in 2001. The sequencing process took more than one 
decade at an immense cost of over 3 billion dollars (Niedringhaus et al. 2011). Today, thanks to 
improvements in bioinformatics and due to the development of high-throughput sequencing 
technologies, it is now possible to map a human genome within a few days (The Economist 2011). 
These high-throughput NGS devices comprise a combination of a synchronized reagent wash of 
nucleoside triphosphates (NTPs) and a synchronized optical detection method. Furthermore, they 
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are based on sequencing by ligation or sequencing by synthesis, including methods such as pyro-
sequencing and reversible chain termination (Niedringhaus et al. 2011). Sequencing machines, such 
as Roche 454 FLX, Illumina Solexa Genome Analyzer, Helico/Helioscope, Applied Biosystems 
SOLiD and Pacific Biosciences SMRT are commonly used (Mardis 2008). These instruments 
permit efficient sample preparation and comprehend a complex combination of enzymology, 
chemistry, high-resolution optics (cf. Figure 6b), hardware and analysis software. Each of those 
technologies tries to amplify single strands of a fragment library, carrying out sequencing reactions 
on the amplified strands which rests upon the “old” Sanger method (cf. Figure 6b). The fragment 
libraries are created by annealing platform-specific linkers to the fragments directly obtained from 
the DNA (or another source). That way, molecules can be selectively amplified by PCR 
(polymerase chain reaction). Helicos and Pacific Biosystems devices are “single-molecule” 
sequencers, which implies that they do not need a PCR prior to the sequencing process. Thanks to 
an improved imaging of sequencing reactions, such as high-definition DNA microarrays, a periodic 
charge-coupled device snapshot of 96 fixed capillaries, running time can be massively reduced. In 
this way, Illumina and Applied Biosystems achieve tens of millions of reads each run (Mardis 2008). 
In whole genome analysis a huge number of genetic variants are investigated using chip analysis.  
 
In order to decrease the costs of sequencing the human genome to less than 1000 USD, the National 
Human Genome Research Institute (2015) has funded teams to develop alternative methods of DNA 
sequencing using scanning tunneling electron microscopes (TEM), fluorescence resonance energy 
transfer (FRET) techniques, single-molecule detection and protein nanopores – known as “Third 
generation technologies”. Two promising methods by Pacific Biosciences and Complete Genomics 
still use the optical fluorescent detection method, while increasing sequencing speed and throughput. 
In contrast, Ion Torrent's relies on ion-sensitive field effect transistors (ISFETs) to elude the need of 
optical detection. Nanopore technologies (cf. Figure 7), as Oxford Nanopore, do not need DNA 
amplification prior to the sequencing process because the change in the conductivity of a nanopore 
molecule is supposed to identify nucleotides. Thus, the identification of nucleotides can be carried 
out directly without any hybridization processes or PCR prior to the DNA analysis. However, this 
technology is still not applicable due to the small DNA throughput achieved (Niedringhaus et al. 
2011).  
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Figure 7: “Nanopore sequencing”, Source: Niedringhaus et al. (2011). 
ssDNA is threaded through a protein (nanopore) which reads out individual bases while the strand remains intact. 
 
3.3. Bioinformatics tools for genetic tests 
 
New genome sequencing methods are challenged by the limited capacity to process, store, revise, 
and interpret data. In this regard, bioinformatics tools in the field of genomic research are a strategic 
discipline, essential for the fast knowledge accumulation in genomic data research.  
 
Thanks to improvements in bioinformatics evaluation methods of genomic data, it has become 
possible to evaluate genetic DNA information with smaller sample sizes and in a cost-efficient way 
(Deutscher Ethikrar 2013:32). Meanwhile, there is a wide-range of bioinformatics software libraries 
available online. Software is an essential tool to analyze high-throughput genetic information at any 
stage. First of all, software is necessary to locate sequences and make techniques of hybridization 
possible. Furthermore, software is essential to assemble genomic fragments, a process which needs 
precise statistical and combinatory algorithms (Deutscher Ethikrat 2013:13).  
 
Bioinformatics software also addresses relevant information on characteristics of genomic data, 
namely coding sequences, the identification of regulatory sequences, as well as introns and exons, 
signals for splicing, cellular characteristics and mutations. Also, bioinformatics tools characterize 
cell biological functions and non-functional protein interactions which are of major importance in 
the field of genetic research. Likewise, the assembly of bigger DNA sections using “fragmented” 
primary data relies on bioinformatics methods. Moreover, such methods offer important diagnostic 
analysis of plausibility control and error detection (Deutscher Ethikrat 2013:38-9). 
 
Importantly, after the primary analysis of “raw” data and data collection and evaluation, 
bioinformatics tools play an important role in data interpretation – the connection of biological 
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information. Genomic sequences can be linked to physiological and biochemical processes in an 
organism.  
 
Another important task of bioinformatics addresses the connection of different biological data using 
mathematical tools and text analysis. This means that gene sections of a genome can be compared 
with physiological and biochemical processes of an organism. Furthermore, the comparison 
between different species is enabled by using bioinformatics tools.  
However, it should be mentioned that bioinformatics results follow inductive hypothesises, which 
implies that evidence of hypothesises can be only given by validating scientific experiments. In fact, 
it can be challenging to draw conclusions from epidemiological data analysis to evidence particular 
clinical cases (Deutscher Ethikrat 2013:39).  
 
Finally, bioinformatics software contributes to confidentiality and data privacy due to algorithms 
that anonymize or decode individual information (which offers the possibility to re-contact data 
donors) (Deutscher Ethikrat 2013:39). 
 
The described software tools are supposed to be the first step to understand biological systems, by 
adapting bioinformatics strategies to non-linear connections between different biological levels. 
“Systems biology” tries to integrate genetic, physiological and biochemical data into a 
computational modeling system of complex biological systems (Bundesministerium für Bildung 
und Forschung 2014, Barrett et al. 2008).  
 
It can be argued that the rapid development of new bioinformatics methods has far-reaching 
consequences for medicine and society that needs ethical reflection. Mass data collection is 
challenged by data confidentiality issues, especially with regard to “unspecific” data collection of 
vast WGS/WES studies. Furthermore, there could be a tendency to establish predictive genetic tests, 
based on genetic data profiles of populations and certain risk groups, as the probability of risk is 
based on the comparison between individual genetic dispositions and disposition of a whole group 
(population) (Deutscher Ethikrat 2013:41-2). Since “systems biology” is still a young research field, 
the described models are expected to progress rapidly in the coming years.  
 
3.4. Adequacy of genetic test methods 
 
The reliability and diagnostic and predictive significance of genetic tests are of major importance in 
research and clinical diagnostics. While research particularly focuses on the technical validity of a 
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genetic test, its medical application is also challenged by the application of epidemiological facts 
and statistical risks that are transferred to individual persons (Jones et al. 2002). Moreover, the 
interpretation of a test - the association of genotype and phenotype - must be evident (Deutscher 
Ethikrat 2013:33).  
  
3.4.1. Technical validity: specificity and sensitivity of genetic tests 
 
The significance of a genetic test strongly depends on the sensitivity of the test applied to a 
particular case. Thus, the technical validity of a test is constituted by its specificity and sensitivity.  
A genetic test is 100% specific if it is positive for individuals carrying a particular characteristic and 
if it is negative for individuals lacking the specific characteristic. Decreased specificity of a test 
means that the test result can be positive for non-carriers (false-positive test results).  
A genetic test is 100% sensitive if carriers of a characteristic are tested positive. A non-sensitive test 
runs risk to overlook positive carriers (false-negative test result).  
A false-positive diagnosis can be harmful if preventive or therapeutic measures are performed 
which are not necessary. In contrast, false-negative test results can lead to harm in case of available 
preventive and therapeutic interventions which are omitted (Deutscher Ethikrat 2013:50-52). False-
positive, as well as false-negative results can be caused by errors during the DNA copy process of 
the test which is essential for the amplification of DNA material. Regarding the practical 
implementation of a test, the risk of wrong test results is never adjusted to zero (Jones et al. 2002).  
 
Both, specificity and sensitivity can be quantitatively measured. It is possible to calculate the 
frequency of false-positive and false-negative test results by using the prevalence of a genetic 
characteristic in the population. Testing rare mutations at many different genetic loci, leads to a high 
number of false-positive results. Likewise, there are many genetic aberrations which are not 
detected in monogenetic disorders due to a high number of non-detected rare alleles and allelic 
heterogeneity (Deutscher Ethikrat 2013:52).   
 
3.4.2. Predictive transfer of statistic risks to individuals 
 
The following paragraph addresses findings of genetic tests that are often predictive statements 
about a future phenotypic characteristic.  
Additionally to the described technical uncertainty, predictive tests can fail to predict phenotypic 
characteristics when transferring epidemiological/statistical risks to an individual. In other words, 
predictive tests try to associate phenotypic and genotypic characteristics by using data collected 
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from populations. Thus, tests cannot individually diagnose people because the risk analysis refers to 
the population risk. The indicated risk cannot surely predict the occurrence of a phenotypic 
characteristic due to additional factors that are necessary for the occurrence of the characteristic 
("penetration"). Hence, even if the genetic test indicates the genotype correctly, an individual 
diagnosis based on the test result cannot be given with certainty. 
In consequence, a prediction of the development of a disease is always linked to a certain 
probability meaning that the individual does not necessarily develop the phenotypic characteristic, 
although it might be likely. This can have very harmful consequences, in particular when preventive 
measures (e.g. mastectomy or ovariectomy of breast cancer patients) are taken. Similarly, it can be 
argued that a test indicating a low risk for certain diseases may harm individuals, especially if the 
individual could have undergone preventive measures (e.g. preventive examinations) (Deutscher 
Ethikrat 2013:57-60).  
 
With regard to multi-factorial disorders, it is even more difficult to interpret complex correlations 
between genotype and phenotype. During the last decades, huge genetic studies (genome wide 
association studies “GWAS”), including an extended number of participants, were conducted and 
aimed for more evidence in this regard (Buchanan et al. 2006). Traits, as disease symptoms, were 
registered and compared with genome wide individual SNP variants or SNP haplotypes. In genome 
wide association studies, cumulative DNA patterns (“markers”) are investigated (Manolio 2010). At 
this point, it should be mentioned that the transfer of the population risk investigated via GWAS to a 
single person is different from the accuracy problem in genetic testing. GWAS is a label of a clinical 
study whereas WGS/WES is the technique or procedure to collect genetic data. Hence, despite the 
conduction of accurate WGS/WES tests, the statistical analysis of genetic variants found in the 
population might not truly represent the population risk: it rather happens that statistical evaluation 
tends to “over-fit” pheno- genotype associations, as non-causal correlations are often brought into a 
causal connection. Likewise, it happens that relevant genes and the interaction between genes are 
not detected, so called “under-fitting”. In order to establish a connection of phenotypic and 
genotypic characteristics, long-term studies need to be conducted (Deutscher Ethikrat 2013:59). 
  
In conclusion, the limitation of disease-genotype associations consists in the transfer of 
epidemiological risks to a single case. However, despite the limitation of using epidemiologic data 
(e.g. from GWAS), genome wide scans may be useful in terms of a general screening for genetic 
variants that influence, for instance, the response to drugs (Manolio 2010).  
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3.5. Databases, data storage and privacy 
 
Following up on the importance of bioinformatics software, databases play a most important role in 
the interpretation process of genetic data. Internationally cooperating biodatabanks which compile 
medical information for research and clinical care build the fundamental basis for further progress 
in genetic data interpretation. However, clinicians face problems, as data of ambulatory patients is 
more and more outsourced to external institutions, which implies that there is less data available for 
research at university centers (Deutscher Ethikrat 2013:42).  
 
Regarding increasing data storage in remote databases, the problem of privacy and confidentiality 
becomes a crucial issue. WGS/WES offers great promise to generate benefits for society. These 
advances depend on large numbers of individuals who are willing to share their genomic data for 
research purposes. Moreover, research results are sounder when the connection between genetic 
variations in whole genome sequence data and specific health and demographic information is part 
of the research project. Therefore, research and clinical power of WGS/WES data is linked to a 
large number of data sets including relevant health and disease information (although, admittedly, 
the use of participant’s names and similar personal information is not necessary) (Presidential 
Commission 2012:22-3).  
 
Genome sequencing determines the complete sequence of DNA in an individual’s cells, including 
all variants within the genome (Presidential Commission 2012:14-9). It can be argued that the 
amount of information contained in the human genome demands thoughtful data collection and 
storage, as “sequence data [is] different from other medical information” (Presidential Commission 
2012:18). 
More specifically, WGS/WES raises concerns about privacy when patients and participants in 
research projects do not want to give access to their sequenced data and genetic information to other 
persons. Thus, if these data is accessed without authorization, it can be considered misuse of 
information. Information revealed in a public space can have negative consequences for an 
individual, as e.g. the impairment of chances to find a spouse, achieving standing in a community, 
or pursuing certain careers (Presidential Commission 2012:20).  
 
In conclusion, it can be considered a topic in itself to draw the line between accessible WGS/WES 
data and data privacy. On the one hand, researchers that are enabled to use vast data resources can 
advance medical understanding and contribute to the public good. On the other hand, the 
consequences of widely accessible data, with a special regard to very delicate WGS/WES data, can 
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possibly harm individuals. 
 
The presidential commission for the study of bioethical issues is addressing crucial questions, as for 
instance, what information about an individual’s genome should be kept private by exploring when, 
and why genomic information is subject to confidentiality, and information security (Presidential 
Commission 2012:21). 
 
4. Conclusion  
 
The aim of this chapter has been to introduce biological terminology, characteristics and the 
application range of genetic tests and to give an overview over sequencing technologies, genetic 
tests and bioinformatics tools, as well as data retention.  
 
So far, it could be pointed out that WGS/WES technologies support significantly discovery and 
understanding in clinical and basic research as a result of the advances in bioinformatics and 
sequencing devices. This makes the informed consent in genome data research a crucial topic taking 
into account the current and future possibilities to use such technologies. Furthermore, this chapter 
puts emphasis on the fact that genetic tests cannot assure absolute accuracy with respect to 
sensitivity and specificity. Also, the correlation of genetic aberrations with phenotypic 
characteristics of an individual has to be handled with care due to complex genotype-phenotype 
relationships and due to the fact that statistical risks, even if appropriately mirroring the 
population’s risk, cannot be linearly transferred to an individual and its health state. 
 
Hence, with regard to the ethical framework and the development of an informed consent for the 
feedback of incidental findings, such technical limits should be taken into account. The technical 
possibilities of WGS/WES research clearly advocate the thoughtful handling of genetic information 
via an informed consent process. 
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Chapter 3. Historical view on informed consent and the return of findings in re-
search  
 
1. Introduction 
 
In the following chapter, I will introduce some of the historical references of informed consent in 
the literature of research ethics. The aim is to present the main ethical hurdles that were identified 
after the Second World War and the answer to them, in terms of guidelines addressing crucial rights 
that should be given to research participants. Furthermore, the development of guidelines for in-
formed consent and the return of findings to participants in research influenced  law and regulation. 
 
In a first step, the historically most important guidelines that impacted on research practice with 
humans will be presented. Subsequently, I will present the example of law and regulation guidelines 
from the U.S., maybe the most common reference for legal frameworks and regulations with regard 
to research using WGS/WES technologies. 
 
2. Historical background on informed consent 
 
Informed consent was originally important in liberal political theory and economic thought which 
can be dated back to discussions during the European Enlightenment in the 17
th
 and 18
th
 century. 
The claim of the social contract tradition is to establish a freely given consent legitimating actions 
of an individual that would be impermissible without consent giving. Basically, informed consent 
was a measure to counter coercive power and despotism. Thus, the basic idea referred to “volenti 
non fit iniuria”, no injury is done where the subject is willing (Steinbock 2007:1).  
The Nuremberg Code was written in 1947, after the Nazi experiments during the Second World War, 
asserting that all research on human beings requires their voluntary consent prior to the participation 
in experiments:  
“[…] This means that the person involved should have legal capacity to give consent; should 
be situated as to be able to exercise free power of choice, without the intervention of any 
element of force, fraud, deceit, duress, overreaching, or other ulterior form of constraint or 
coercion; and should have sufficient knowledge and comprehension of the elements of the 
subject matter involved as to enable him to make an understanding and enlightened decision. 
[…]” (The Nuremberg Code 1949, Article 1).  
 
The first article of the Nuremberg Code uses the term “voluntary consent” instead of “informed 
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consent”, which emphasizes the demand of a freely given consent in the historical light of the Nazi 
crimes. However, the literature on research ethics considers the Nuremberg code as a paradigmatic 
reference of “informed consent”. Referring to article 1 of the Nuremberg Code, three main 
characteristics of voluntary consent can be distinguished: the capacity to give consent, non-
interference in terms of “free power of choice” and “sufficient knowledge and comprehension”.  
 
Apart from the Nazi trials, another exemplary case in history of a clear infraction of research 
participant’s informed consenting can be considered the Syphilis Study conducted in Tuskegee and 
Alabama during 40 years between 1932 and 1972. The study was promoted by the Federal Public 
Health Service in the US and acted against an adequate comprehension of the informed consent 
requirement (Centers of Disease Control and Prevention 2013). Since some participants remained 
without treatment despite the availability of penicillin, researchers had a control group to investigate 
the “natural progression of the disease”. Although informed consent sheet was signed by the 
participants – and one major aspect of the informed consent requirement was met – the participation 
resulted in miscomprehension, as the participants were not informed about the availability of 
treatment, treatment provision, or the risks of omitted treatment (Johns 2008:86). This means that 
the missing component of “sufficient knowledge and comprehension” did jeopardize the possibility 
to give proper informed consent and moreover and the voluntariness of participants which also 
strongly depends on knowledge and comprehension. 
 
In 1964, the World Medical Association launched the Declaration of Helsinki, which put emphasis 
on the importance of informed consent. The Declaration of Helsinki is undergoing a continuous 
revision process and is considered one of the foremost international guidelines for research with 
human beings (Presidential Commission 2011:97).  
 
Further mile stones in the guideline development were the Belmont Report in 1978 (The National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 1978), 
the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and 
Behavioral Research, which published reports on Protecting Human Subjects (1981) and 
specifically addressed informed consent. In 1981, the FDA (US Food and Drug Administration) 
regulation guidelines were revised using the Belmont Report as a template. The Council for 
International Organizations of Medical Sciences presented in 1983 International Ethical Guidelines 
for Biomedical Research Involving Human Subjects (revised in 1993 and 2002) (CIOMS and WHO 
2002). In 1991, the U.S. Department of Health and Human Services issued the Federal Policy of 
Human Subjects, the Common Rule, which was adopted by 18 federal agencies. Also, the Tri-
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Council policy statement (2014) is considered one of the important documents for the protection of 
human research individuals (WHO 2015). 
 
The following timeline gives a historical overview of developments in U.S. research ethics and 
informed consent.  
  
 
                               Table 1: “Historical overview research ethics guidelines” Source: Berg et al. (2001:44)  
 
Contemporary discussions suggest that informed consent should play a more important role in 
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biomedical issues than in the late 1940s, when the Nuremberg Code was written. For instance, 
informed consent requirements have been extended to clinical settings (Steinbock 2007:4). 
 
As shown in the Table 1, regulations (suggested by several guidelines) for the use of personal and 
medical information and human tissues were implemented in clinical and research practice.  
Furthermore, the informed consent requirement has been incorporated into the regulations 
governing data protection, use of human tissues and genetic technologies, and is thus mandatory for 
the secondary use of information and tissues (Steinbock 2007:4-5).  
These examples show that the informed consent guidelines have to be continuously adapted in order 
to guide informed consent practices with respect to novel and future developments in medicine. For 
instance, in the Bioethics Commission’s report “Privacy and Progress in Whole Genome 
Sequencing” (Presidential Commission 2012), sequencing of whole genomes is exemplified as 
technological advance that needs evolving concepts of informed consent. Yet the complexity and 
the data volume of WGS/WES needs to include more advanced elements for obtaining informed 
consent, such as the expected risks, benefits, likely outcomes, as well as the emphasis that 
uncertainty is inherent to sequencing technologies (Grady 2015). 
 
Steinbock (2007:2) points out that informed consent is nowadays so well established in clinical and 
research practice that its justification is rarely questioned.  
 
In this section, a short historical overview on the informed consent requirement and the 
development of guidelines has been presented. In the next section, the current situation regarding 
legal implementations of the informed consent requirement, as well as on the return of incidental 
findings will be given. 
 
3. Law and Regulation Guidelines: the Case of the United States 
 
In the following paragraphs, the scope of informed consent in whole genome research settings, as 
well as the legal guidance regulating the return of findings will be depicted. The example of the U.S. 
may be the most demonstrative case for the implementation of sequencing technologies due to its 
pioneering work in the application of WGS/WES and in guideline and regulation development.  
Furthermore, most of the English-language literature dealing with the implementation of informed 
consent and the return of findings focuses on legal frameworks implemented in the United States. 
The guidelines that are subject to this thesis and serve as references are first and foremost issued by 
U.S. American institutions (e.g. the Presidential Commission for the Study of Bioethical issues). 
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Legal guidance regarding genetic non-discrimination, such as the U.S. federal “Genetic Information 
Nondiscrimination Act” (GINA) addressing the question how to deal with genetic data and data 
protection of large-scale genomic data (Presidential Commission 2012:52) will not be part of this 
chapter, as the scope of the dissertation will be on the counseling process between research bodies 
and research participants and does not focus on confidentiality issues or the impact of data 
disclosure to third parties. 
 
Federal regulations were codified by the U.S. Department of Health and Human Services in 1991 
(HHS 1991) and are legally binding rules for conducted research involving human participants. 
Eighteen federal agencies have implemented the Common Rule. Additionally, the U.S. Food and 
Drug Administration (FDA) codified its policy for the protection of human subjects and regulates 
research trials for products which are in the scope of FDA (Figure 8 “Federal Regulation of Human 
Subjects in Research”, Presidential Commission 2011). 
 
 
Figure 8:  “Federal Regulation of Human Subjects in Research” 
Source: Presidential Commission for the Study of Bioethical Issues (2011:31) 
 
The Common Rule applies to research with human subjects and is promoted by the 18 federal 
departments or agencies. Importance is given to general requirements for informed consent, 
including an explanation of the research study, the statement of expected benefits and potential risks, 
an explanation of confidentiality, available medical care and compensation for injuries that can be 
traced back to the research experiment, and to the statement of voluntariness - withdrawal from the 
research study at any point of time (Presidential Commission 2011).  
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All 50 states have adopted some informed consent law, but there are still huge differences regarding 
legal obligations in clinical and research settings between different states (Presidential Commission 
2012:133). For instance, completely different legal obligations are coming into effect, when genetic 
information is generated and stored as part of the research protocol (Presidential Commission 
2011:133).  
 
Regarding the case of the United States, there is no federal law or state law addressing the return of 
research results to individuals participating in research studies as yet (Wolf 2012). Nonetheless, 
there are regulations, e.g. the Federal Policy for the Protection of Human Subjects, protecting 
humans enrolled in research projects. Notably, the regulation document addresses the informed 
consent process, and in particular, the information disclosure of potential benefits and risks 
connected with research projects. Moreover, the ICH-GCP (ICH-GCP 1996) harmonization 
guidelines defined informed consent as “[…] the process by which a person freely confirms their 
willingness to participate in clinical research after having been informed of all parts of the study 
that are relevant to the individual’s decision to participate”. 
 
Potentially beneficial or harmful information are crucial features attributed to research findings 
(Presidential Commission 2013:81). In the United States, regulations on the revealing of patient-
specific results concern results obtained in research laboratories that are certificated as CLIA 
laboratories, laboratories committed to federal quality standards. The Clinical Laboratory 
Improvement Amendments of 1988 (CLIA) regulations include federal standards which can be 
applied to “[…] all U.S. American facilities that test human specimens for health assessment or to 
diagnose, prevent, or treat disease.” (Centers of Medicare and Medicaid Services 2015).  
 
Since only few research laboratories choose to obtain CLIA certification (CLIA certification covers 
around 251,000 laboratory entities, Centers of Medicare and Medicaid Services 2015), it is 
currently under discussion whether those laboratories without CLIA certificate should return 
findings to research participants (Presidential Commission 2013). It was furthermore argued that 
findings generated in non-CLIA institutions should be revealed as long as they are indicated as 
research findings and not as clinical findings (Fabsitz et al. 2010). However, this can be considered 
rather a particular problem connected to the U.S. regulations than an ethical concern. 
 
In 1999, the National Bioethics Advisory Commission (NBAC) favored the model not to return 
incidental research findings, except in rare circumstances. Over time, several organizations and 
advisory commission complemented guidelines, suggesting that patients and participants should be 
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offered to learn about intended and incidental findings which can affect their health (Wolf et al. 
2012, Bradbury, McCormick and Robson 2014). The American College of Medical Genetics and 
Genomics (ACMG) (2013)
1
 developed recommendations for the report of incidental findings in the 
context of WGS/WES. The ACMG emphasizes the importance of disclosing the possibility of such 
incidental findings prior to WGS/WES, as well as the importance of reporting incidental results 
which are outlined in the recommendations to individuals in a clinical context (Green et al. 2013). 
The Presidential Commission (2013) also released guiding principles specifically considering return 
of findings in WGS/WES research. Importantly, those recommendations give weight to the 
anticipation of the potential of incidental findings, the communication of this potential and a plan 
for the disclosure of findings to research participants. Moreover, topics like the share of decision 
making or the right to reject receipt of incidental findings are addressed (Presidential Commission 
2013).  
 
Considering minors, there can be additional questions raised with regard to the legal feasibility of 
returning future WGS/WES finding. Federal law sets the required age for consent at age 18, while 
state laws allow consent by minors who are older than 14 years (The Family Educational Rights and 
Privacy Act, 20 U.S.C. §1232g; 34 C.F.R. §99). For instance, the Presidential Commission 
(2012:148) reproaches the federal and state laws for not regulating the return of future findings in 
case of minors. Generally it is concluded, that most genetic aberrations should not be predicatively 
tested in minors. Nonetheless, WGS/WES comprises genetic analysis of all genes. Thus, it is 
unclear if researchers should feel compelled to re-contact these children as adults, in particular if 
there is evidence on other genetic aberrations at  future points of time (Presidential Commission 
2012:148-9). 
The American College of Medical Genetics and Genomics (ACMG) (2013) states that seeking for 
genetic aberrations could be medically important to a child’s future or the family even if such 
findings are linked to an adult-onset of disease. The ethical concerns about providing the clinicians 
of children with genetic risk information are outweighed by the potential benefits to the future 
health of the child and the child’s parents (Green et al. 2013). 
 
4. Conclusion  
 
The presentation of attempts in the course of history to improve informed consent requirements and 
                                                 
1
 There has been an update in 2014 by the ACMG emphasizing that there is a consensus among ACMG members that 
patients should have an opportunity to opt out of the analysis of medically actionable genes when undergoing whole 
exome or genome sequencing (ACMG 2014: “ACMG Updates Recommendation on “Opt Out” for Genome Sequencing 
Return of Results”). 
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how informed consent is brought into current legal practice has been the main objective of this 
chapter. Especially the historical review on informed consent shows that informed consent has been 
always adapted to new research fields or responded to historical events which clearly infracted re-
search individuals’ rights. Applied to the case of WGS/WES, it can be put on record that the devel-
opment of informed consent has not yet come to an end. This means that new technologies, such as 
WGS/WES, demand a continuous adaption of the informed consent requirement. Also, since the 
implementation of WGS/WES procedures in clinical research is accelerated due the huge cost re-
duction potential of sequencing technologies, an informed consent model tailored to WGS/WES 
would substantially contribute to a further adaption of informed consent to these external conditions.  
 
Regarding the aspect of informed consent in the feedback process of incidental findings, it is of ut-
most importance to point out, that homogenous legal frameworks are still missing (example in the 
United States). This uncertainty demonstrates that there is an urgent need to clarify recommenda-
tions on the return on findings and that ethical frameworks are needed to guide the return of re-
search results. With regard to Chapter 4, there will be a major paragraph carving out what kind of 
findings should be necessarily reported to research individuals. 
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Chapter 4. Ethical framework of informed consent models in WGS/WES and 
the disclosure of genomic data research findings 
 
1. Introduction 
 
The objective of this chapter is to introduce a new consent model that I call the “iterative feedback 
model” for whole genomic data collection and disclosure of incidental findings in human health 
research studies. The model approaches the ethical demands to informed consent models in the 
specific setting of research studies using WGS/WES procedures by adapting to specific problems 
and characteristics arising in the context of WGS/WES data and the disclosure of incidental 
findings. 
In order to introduce the model, I will first establish and justify the practical scope of the present 
dissertation. Secondly, I will reconstruct already existing informed consent models for research 
using WGS/WES procedures. In the next step, those models will be evaluated by challenging them 
with ethical principles that are considered crucial in research ethics (cf. Appelbaum et al. 2014). 
Finally, the “iterative feedback model” will be developed and evaluated on the basis of the ethical 
framework while focusing on the disclosure of incidental findings to research subjects. 
 
2. Case study 
 
The objective of the following case study is to present a practical and intuitive application of 
WGS/WES in a research setting. The analysis of a real case is supposed to facilitate the understand-
ing of ethical issues and its further discussion when considering the informed consent process for 
the disclosure of incidental findings in research studies using WGS/WES procedures.  
More specifically, the example chosen for analysis is a case of GWAS (genome wide association 
studies) which have been introduced in chapter two (cf. “Predictive transfer of statistical risks to 
individuals”). GWAS is a subtype of human health research using WGS/WES procedures. In the 
broad application range of WGS/WES procedures, GWAS specifically examine a big number of 
genetic variants in different individuals and associate them with phenotypic traits (Buchnan et al. 
2006) like e.g. rare diseases. GWAS demonstrate the case of incidental findings that likely appear 
when searching for genome wide associations with traits due to the investigation of many genes and 
of many participants. Therefore, the further ethical analysis of research studies using WGS/WES 
procedures is in particular tailored to the ethical problems arising in the course of a particular 
GWAS of rare diseases.  
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Case: The rare diseases genomes project (NHS-UK) 
 
In 2013, the “Rare Diseases Genomes Project” was announced in the United Kingdom, a 
collaborative project between the University of Cambridge, Illumina Inc. and Genomics 
England Ltd. It is a project that aims to sequence 10,000 genomes of rare disease patients within 
three years and is conducted together with England’s “100k Genome Project” 
(www.genomicsengland.co.uk) (Perdeaux 2013). Patients with rare diseases and conditions that 
were likely to have a genetic basis could participate in the project. Scientists hope that the 
projects “[…] will bring enormous improvements to the care of patients with rare diseases […]” 
(Bradley 2014). 
 
Usually, patients suffering from rare diseases face a long time until they obtain a diagnosis. For 
instance, two siblings with an unusual muscle wasting disease had to wait for 20 years until they 
were diagnosed at a cost of of more than 14,000 pounds. Whole exome sequencing which cost 
approximately 1000 pounds revealed that heterozygous mutations in the SACS 
(www.omim.org/entry/604490) gene were likely to be disease causing (Perdeaux 2013).  
 
Furthermore, researchers participating in the project are allowed to access the data and use them 
as de-indentified information for epidemiological and drug discovery studies or to identify 
patients for clinical trials. The NHS (National Health Service) assured the security of the 
collected data (Perdeaux 2013).  
 
This case brings into play several interesting issues to consider. First of all, the example shows that 
using WGS/WES procedures in research studies can be an adequate and common method to 
investigate new genes that could be of importance for the pathogenesis of disease, not least due to 
the improving sequencing technology allowing fast and cheap data collection (Niedringhaus et al. 
2011). Notwithstanding, there are currently no statutes directly regulating the return of research 
findings to research participants (Presidential Commission 2013). 
 
However, whole genome sequencing produces a vast amount of data of research individuals which 
can have huge implications for the life of these individuals. For instance, it is very likely to find a 
great number of variants of unknown significance, complicating the interpretation of results. 
Furthermore, “incidental findings” could reveal that a research participant is at risk of developing a 
disease which is unrelated to the former physiological abnormalities. In this regard, the question 
might be, whether to return incidental findings or not. Since the return of information may have 
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implications for the participant’s decisions, as e.g. reproduction, advocates of the principle of 
“personal utility” (cf. “theoretical framework”) might favour the full disclosure of relevant 
information if the participant agrees. Moreover, it is frequently argued that supporters of concepts as 
personal entrustment or reciprocity demand the disclosure of all relevant information as part of the 
researcher’s obligations (Secretary’s Advisory Committee on Genetic Testing 2000). For this reason, 
some have argued that researchers ought to disclose all findings independently of the clinical 
implications they may have (Whitney and McCullough 2007).  
 
In contrast, it can be criticized that incidental findings without “analytical” and/or “clinical validity” 
and/or “clinical utility” do not contribute to a meaningful information return, as the data does not 
reveal significant findings that could have consequences for the participant. Other authors suggested 
that findings should at least exhibit reproductive significance (the extent to which a finding has 
medical implications for one’s self offspring) or the seriousness of potential harm (Claufield et al. 
2008).  
Additionally, such data is prone to misinterpretation by participants who are probably not familiar 
with the distinction between analytical validity, clinical validity and clinical utility. Another issue 
related to the question of confidentiality, is the disclosure of findings, once they arise, to other 
family members who could be affected by the same genetic aberrations. This might be a serious 
problem especially in the case of rare diseases, as individuals with the same syndrome are often 
related. 
 
3. Scope of the thesis 
 
In this section, I will state the scope of the main thesis in order to develop the iterative informed 
consent model.   
 
Scope of the iterative inform consent model. In this work I will focus on the informed consent 
process of potential individual research participants in human health research study using whole 
genomic sequencing (WGS)/whole exome sequencing (WES) procedures, as well as on the 
disclosure of incidental findings after a study is conducted.  
 
An Informed consent model is the application of informed consent theory in practice. Informed 
consent models incorporate general principles and the groundwork of informed consent theories by 
interpreting them and applying them to a particular question or problem. In this dissertation, the 
particular problem addresses how incidental findings, if any, should be revealed to individual 
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research participants in studies using WGS/WES procedures. Ideally, an informed consent model 
would be a consistent and useful application in practice of the informed consent requirement 
(Merritt 2011). 
 
Referring to research studies with human subjects using WGS/WES procedures, I will focus on 
the informed consent process in research projects involving participants who are already patients in 
a medical context, excluding healthy persons. The term WGS/WES procedures refers to technical 
methods that are used to inquire conditions, as diseases. 
 
The data release of WGS/WES research studies can be subdivided in several categories. As primary 
objective, human health research studies aim for a public release of data via publications. Generally, 
genomic data can deal with general study results, or with individual study results, comprising 
incidental findings not primary sought for in research studies involving human research subjects 
(Secretary’s Advisory Committee on Human Research Protections 2000). The definition of 
incidental findings, respectively the heterogeneity of definitions found in the literature will be 
discussed below. 
 
Furthermore, research studies are not primarily conducted to obtain significant results for clinical 
testing, as research results do not always comprise clinically valid data like clinical tests. However, 
even if research results cannot provide the accuracy of clinical testing, there might be important 
findings to report (that could be validated in further clinical studies). As an alternative to the 
recommendations by the National Bioethics Advisory Commission (NBAC) (1999), in which the 
disclosure of incidental findings is only recommended in case of significant implications for the 
participant’s health and in case of an action available to treat the associated disease, I will develop a 
novel framework for the disclosure of incidental findings (cf. “General argument: constructing the 
iterative feedback informed consent model”).  
 
3.1 Ethical problems outside the scope of the current presentation of the iterative in-
formed consent model 
 
There are many ethical problems arising in WGS/WES research studies with human subjects that 
are not focus of the thesis, but valuable for further ethical analysis and discussion. Particularly 
important ethical problems closely connected with the topic of the thesis will be mentioned in the 
following text, but will not be addressed due to the limited space of the thesis. However, I believe it 
is important to state these problems explicitly to complement the positive definition of the scope of 
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the thesis in the previous section. Also, they might be interesting paths to follow in future research 
and extensions of the iterative informed consent model. 
 
Obligations towards third parties. Researchers’ obligations towards third parties are not addressed 
in this dissertation. For instance, third parties, as family members, could be involved in the 
WGS/WES disclosure process of findings due to their close degree of relationship to the research 
participant. Even though the thesis does not address these ethical issues, I will adopt the principle 
“not to harm third parties” which implies that in case of conflicts of interests between research 
individuals and other parties, the integrity of other individuals will be prioritized.  
 
Confidentiality. Likewise, I will not focus on confidentiality issues towards the individual research 
participants. Thus, the ethical revision of further data use in epidemiological and drug studies, as 
well as in data retention, will not be discussed. As a side note, it can be mentioned that data 
protection and dealing with collected large-scale genomic data and its privacy concerns is one big 
issue raised in the scope of the Human Genome Project launched in 1990. One important task 
addresses the question how to safely store genetic information that has grown exponentially 
(Presidential Commission 2012:52). Confidentiality is of utmost importance to protect participants’ 
data that should be restrictedly accessible to third parties. 
 
Storing, sharing and distributing genomic information. Lastly, storing and distributing genomic data 
is not within the scope of this thesis. An example linked to data retention and the research making 
use of already stored data is biobank research that is usually linked to practical considerations 
distinct from other research settings. Biobank research will be also excluded from the focus of this 
thesis. One major problem that we face in the context of biobanking is the de-identification of 
stored data that cannot be connected to particular individuals, which makes re-identification 
difficult (Presidential Commission 2013:80).  
 
4. Reconstruction of the theoretical framework for the ethical discussion 
on incidental findings  
 
4.1 Whole genome data 
 
In order to design a consent model for the disclosure of incidental findings in human health research 
using WGS/WES procedures, the advantages and disadvantage of several consent models as well as 
crucial ethical principles should be taken into account. However, prior to this analysis it is necessary 
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to characterize whole genome data. This approach shall furthermore build the basis for the 
development of an ethical analysis tailored to the characteristics of data collected during the 
conduct of research studies using WGS/WES procedures. Generally spoken, characteristics of 
WGS/WES data are crucial for the evaluation of an informed consent model for the disclosure of 
incidental findings in research studies using WGS/WES procedures, in order to advocate a more 
specific, broad, autonomous, etc. informed consent, as it will be discussed in the course of chapter 
four.  Box 1 shows the characteristics of WGS/WES data I considered important for the evaluation 
of informed consent models. In the following paragraph, those characteristics will be explained in 
more detail. 
 
One important characteristic of WGS/WES data for the evaluation of an informed consent model is 
the predictability of health outcome. Predictable health outcomes usually attribute a probability to 
a future health state whereas inevitable health outcome are certain events. As explained in chapter 
two, predicting health outcomes is always based on a statistical risk that is transferred to an 
individual case. In this way, whole genome data can eventually be linked to future health events of 
the research participant and his family members. However, the probability linked to a health 
outcome indicates a chance for the individual to develop a disease. Even if a research finding does 
not cause physical harm to the participant immediately after testing, the knowledge about the 
finding can lead to psychological harm, emotional or cognitive disturbances such as worry, fear, 
depression or anxiety (Institutional Review Board for Social and Behavioral Sciences University of 
Virginia 2015), due to possible future health impairments. Thus, when designing an informed 
consent model, it should be taken into consideration that predictable health states can be a source of 
psychological harm.  Furthermore, therapeutic and preventive measures could have severe physical 
consequences for participants (e.g. a mastectomy and oophorectomy in case of an elevated risk for 
breast and ovarian cancer). Therefore, an informed consent model should explain the alternatives of 
therapeutic and preventive measures and the inherent risks corresponding to the alternatives an 
individual has.  
 
Moreover, collected data include a set of very heterogeneous information that can refer to a 
variety of psychological or physical predispositions. For instance, such findings can be associated 
with mental disorders like Alzheimer’s disease or Huntington’s disease. Some gene aberrations 
found in WGS/WES data sets can only be applied to one sex of the immediate family tree (as 
BRCA1/2 is more severe in females). Furthermore, the risk to develop a certain disorder varies 
among diseases and their correlated genetic aberrations. Gene mutations show different risks for the 
development of a certain disease.  
48 
 
Another characteristic of WGS/WES data for the evaluation of informed consent models is 
irreversibility of genetic information. Once, genetic information is disclosed, there is no reclaiming 
it, as an individual’s genetic information does not change over time (Genomics law report 2009). 
This applies to germ line mutations that are present in all somatic cells during the whole life of an 
individual. In contrast to somatic mutations that are found only in certain cell types (e.g. cancer 
cells) and which can change their genetic disposition, germ line mutations are enduring entities. 
Regarding the example of the GWAS of the rare diseases genomes project, it is in particular focused 
on a search for germ line mutations causing certain health conditions. Research on this type of 
mutation implies that at the point of time when information is revealed, unchangeable facts are 
disclosed which potentially change a person’s life-style, expectations, planning etc. Thus, genetic 
information could be the basis for discrimination for an individual`s whole life.  
 
Interpretation and knowledge about genetic data change over time. For instance, variants of 
unknown significance can “turn into” scientifically confirmed mutations or variants with or without 
pathogenic effects after the introduction of new research results. “Genetic information” is based on 
genetic loci which are statistically correlated with phenotypic events (as diseases). Without the 
correlation between phenotype and genotype, genetic analysis cannot be used in terms of a medical 
exam (cf. Chapter two, 2.4 “Diagnostic, prognostic and predictive genetic analysis”). Anticipating 
the demands towards an informed consent model, changing interpretation and knowledge about 
genetic data can justify a repetitive (iterative) genetic counselling process.   
 
Uncertainty is a crucial characteristic that should be taken into consideration when dealing with 
WGS/WES data. There are unclear phenotype-genotype correlations (variants of unknown 
significance). In many cases, a correlation may not be fully understood (variants of unclear 
significance) or remains unknown at the time of study.  
 
The term privacy applies to WGS/WES data and the evaluation of informed consent models. 
Genomic data is private and delicate data. The term “private data” is linked to personal and intimate 
data which demands thoughtful consideration and analysis (cf. theoretical framework).  
 
Finally, with regard to the evaluation of informed consent models, it is important to consider the 
connectedness of information as well as the reach of genetic data. Genetic mutations also concern 
relatives and off-spring and are of importance for family planning.  
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Box 1 
 
1. Characteristics of WGS/WES data 
 
1.1.Characteristics of WGS/WES information and interpretation 
 Heterogeneity. Heterogeneous information (information concerning mental, 
physical dispositions, disorders, minor risks etc.) 
 Irreversibility. Information does not change over time. Genetic information is 
contained in the genetic code linking genotypic and phenotypic characteristics 
(gen-protein relationship). 
 Interpretation. Interpretation (propositional knowledge) of genetic information is 
based on the correlation of genetic loci and the occurrence of events affecting an 
organism/individual. 
 Connectedness. The disclosure of genetic information affects not only individuals 
but relatives and off-spring. 
 Uncertainty. There are unclear phenotype-genotype correlations (variants of 
unknown significance) 
 
1.2.Consequences for return of results (ROR) 
 Predictability. The probability to develop a certain disease, disorder or another 
physical event can be indicated. 
 Reach. Genetic information can involve family members and off-spring. 
 Privacy. The term “private data” is linked to personal and intimate data. Genetic 
data is private data. 
 
 
 
WGS/WES data is a raw, but already purified (from inaccurate sequencing results) data set of the 
base pairs constituting our genome, respectively exome. Data is obtained by sequencing DNA 
fragments. Those sequenced base pairs are eventually reassembled in the data set. 
 
WGS/WES information (the genetic code) refers to genes which have the informational property 
that they code for amino acid sequences of protein molecules via transcription and translation 
processes (Godfrey-Smith and Sterelny 2007). The protein molecules interact in the organism, 
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constituting the phenotype of a being. Thus, the information of genetic data is contained in the code. 
 
Knowledge about genetic information is propositional knowledge of facts about the statistical 
correlation of changes in base pairs and events affecting the whole organism via protein 
modification. Together with the knowledge about pathway interactions between protein molecules, 
physiological processes can be partially reconstructed and eventually linked to diseases. 
 
4.2 Key concepts for discussing the disclosure of incidental findings in genomic re-
search 
 
The discussion about the return of genomic data and the disclosure of incidental findings has 
generated a particular vocabulary that it is necessary to introduce in order to avoid confusion when 
discussing the advantages and disadvantages of several informed consent models, included the 
“iterative feedback model” presented here. As Eckstein et al. (2014) state, lack of clarity about key 
terms can sometimes lead to the contrary recommendations for the return of findings. Hence, it is of 
great importance to define these terms. 
 
I will begin with a first general and usual distinction in practical philosophy between “concepts” 
and “conceptions”. A “concept” refers to the general structure of A, while various “conceptions” of 
A are more particular, and even more contested interpretations of the general concept. Thus, 
concepts are more formal representations of A, while conceptions refer to its substantive 
formulations (Rawls 1999:19). The concepts that will be presented below, e.g. the concept of 
“actionability” (in the sense of applicability, practicality) can be interpreted in different ways. For 
instance, the range of conceptions of “actionability” can reach from “making life-planning decisions 
more concrete” to “availability of specific treatment”. The distinction between concepts and 
conceptions is important in ethics because many practical problems occur if different conceptions of 
the same concept are not appropriately applied to or used in a certain context.  
 
 “Analytic validity” of genetic tests indicates how accurate and reliable the test measures a certain 
genotype of interest (Secretary’s Advisory Committee on Genetic Testing 2000).  
 
The term “clinical validity” of genetic tests refers to the accuracy to predict a clinical outcome 
(Eckstein et al. 2014). Likewise, the NHLBI Working Group defines “clinical performance”   
equivalently to clinical validity of a genetic test as “including its clinical sensitivity and specificity 
(as related to disease), and positive and negative predictive values” (Richardson 2008, cf. Chapter 
two “Adequacy of genetic test methods”). However, this definition is challenged by the fact that 
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genomes show heterogeneity of phenotypes, of gene penetrance, as well as biases in the study 
populations. Thus, functional relationships between genotype and phenotype remain sometimes 
unclear (Wolf et al. 2008). For instance, regarding rare diseases, there can be several genes that 
come into consideration when searching for a disease causing mutations. Also, regarding the small 
number of participants that can be investigated (due to the rareness of a disease), it can be difficult 
to generalize phenotype-genotype correlations.  
 
“Clinical utility” is linked to the risks and benefits resulting from test use (Burke 2009). Burke 
(2009) defines clinical utility furthermore as a proven therapeutic or preventive intervention that has 
the potential to improve a health state connected to the genetic disposition. In contrast, the NHLBI 
Working Group (2006) refers rather to the likelihood that a performed test will lead to an improved 
health outcome, which offers a more moderate conception of clinical utility. Thus, this conception 
of clinical utility takes future beneficial treatments into consideration that are  not yet available 
today. To tie up to the example of the rare diseases, the outcome of a genetic test should potentially 
improve the future health state of an individual, e.g. via a (future) more target-specific treatment.  
Likewise, the term “clinical relevance” is closely linked to clinical utility, but emphasizes the 
requirement of a clinician’s knowledge about an individual’s history, family, and environment 
(Kohane and Taylor 2010).  
 
The concept of “general/personal utility” of a genetic test can differ from clinical utility. It might 
be beneficial for research participants to know about results, even if they remain unrelated to 
clinical benefits (Secretary’s Advisory Committee on Genetic Testing 2000). Thus, even if some 
research results lack clinical utility because there are no available medical interventions, reporting 
such findings might be considered important, because it is of interest for the person’s own sake 
(Shkedi-Rafid 2014). This more participant/patient-centered approach acknowledges that actions 
beyond disease prevention, monitoring and treatment can have meaning for research 
participants/patients (Gordon 2009). 
 
“Actionability” of research findings can be understood in different ways (Eckstein et al. 2014). 
First of all, actionability of research findings can be interpreted in a broad sense of making possible 
life-plan decisions with regard to particular genetic information. For instance, revealing a research 
participant that he or she carries a mutation in the Huntington’s gene can make life-planning 
decisions more actionable with regard to reproduction, settling family affairs, etc. Likewise, 
actionability can be understood as the potential for an improved health outcome including other 
actions that might change the course of disease (Fabsitz et al. 2010). Coming back to the example, 
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support by family members or by psychologists could at least improve the psychological harm that 
is part of the course of disease.  
Secondly, in a narrow sense, “actionability” refers to “medical actionability” (Green et al. 2013) 
like the availability of effective medical treatment or prevention. In the case of Huntington’s disease, 
effective treatment to fight the disease and prevention is currently not available. Hence, mutations 
in the Huntington’s gene are not medically actionable at this point in time, but can be actionable in a 
broad sense.  
 
With respect to an individual’s preference whether to know about a research finding or not, the term 
“volition” comes into play. A common formulation is “the expressed preferences of research 
subjects” (Rothstein 2006). 
 
4.3 Informed consent in research using WGS/WES 
 
4.3.1 The general definition of informed consent 
 
The primary aim of this work is to develop an informed consent model for the disclosure of 
incidental findings in human health research using WGS/WES procedures. In this regard, I ought to 
define what I understand by informed consent. The understanding of informed consent will be 
based on the general definition given by Eyal (2011): 
 
“Informed consent is shorthand for informed, voluntary and decisionally-capacitated 
consent. Consent is considered fully informed when a capacitated (or competent) patient or 
research subject to whom full disclosures have been made and who understands fully all that 
has been disclosed, voluntarily consents to treatment or participation on this basis. […] In its 
most important role in bioethics, informed consent is a legitimacy requirement for certain 
actions. Inadequately informed consent makes certain intrusions impermissible. […] 
Roughly, when a sufficiently capacitated adult does not give sufficiently informed and 
voluntary consent to intervention in her body or her private sphere, then, at least when the 
intervention is substantial, not trivial, and absent severe jeopardy for third parties, the 
intervention is impermissible—even when it seeks to assist her, physicians recommend it, 
third parties would benefit from it, and the patient herself had repeatedly consented to it 
before expressing a change of mind.” (Eyal 2011, emphasis added). 
According to this approach, informed consent pursues three aims: (1) full transmission of relevant 
information, (2) full comprehension as well as (3) voluntariness of subjects that consent. 
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Importantly, by “full transmission of relevant information” I understand the insurance that the 
individual receives all relevant information to make an informed choice. As stated in the Nuremberg 
Code (1949, Article 1), research subjects should have “[…] sufficient knowledge […] of the 
elements of the subject matter involved as to enable him to make an understanding and enlightened 
choice.” For instance, relevant information can be understood as explanation of all health 
impairments that could be revealed by WGS/WES and that would be important to the research 
individual. “Full comprehension” means that individuals understand the relevant information, so as 
to be able to act autonomously (autonomy will explained in more detail in section “ethical 
principles in the discussion of informed consent models for the return of findings”) based on the 
comprehension of the given information. It should be mentioned that the transmission of relevant 
information is different from comprehension which has to be considered in the context of the 
individuals’ culture, education etc. (Amaechi Agu et al. 2014). Moreover, the transmission of 
“complete/full” information from the researcher’s point of view could overload the research 
subject’s capacity of decision making. Thus, information revealing has to be adapted to cultural and 
educational background and the relevance of information evaluated in the light of these external 
factors. Amaechi Agu et al. (2014) argue after having conducted a survey in Nigeria on the 
understanding of information when informed consent is taken, that the majority of interviewed 
individuals desire to be involved in decision-making about their health state even though their 
understanding is often limited. Hence, they argue that there is a need to simplify information that is 
often too extensive.  Finally, voluntariness of participation refers to a free and uncoerced act of 
decision-making without fraud. Potential barriers of voluntariness can be (1) “coercion”, (2) “undue 
inducement” or (3) “no choice” situations (Eyal 2011). (1) “Coercion” is defined as “[…] threat to 
make someone seriously worse off than she is or should be, unless she consents.” (2) “Undue 
inducement” is a term usually meaning that something is being offered that is alluring to an 
individual which leads to an irrational choice (e.g. cash in hand if the individual undergoes a certain 
treatment). Lastly, (3) “no choice” options refer to the lack of decent alternatives for an individual 
(Eyal 2011). 
 
Eyal’s already comprehensive definition of informed consent can be compared with other important 
literature specifically addressing informed consent. This approach aims to complement the 
definition and puts it into the context of important previous definitions on informed consent for 
research. However, it will be shown that other references will get back to the three essential 
elements stated by Eyal (2011): (1) full disclosure of relevant information (2) full comprehension 
and (3) voluntariness.  
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Faden and Beauchamp (1986) consider informed consent as “autonomous authorization” 
comprising a complete and adequate information background, full intentionality and the absence of 
controlling. These requirements are directly comparable to (1) full transmission of relevant 
information and (2) comprehension, as the information background is based upon the full disclosure 
of relevant information and its understanding, as well as (3) voluntariness which is the absence of 
controlling and a free act. From another perspective, informed consent is one application of the 
principle “respect for persons” in the Belmont Report, (National Commission 1979) a founding 
document of research ethics. The principle of “respect for persons” demands, similarly to the 
definition by Eyal (2011), that “[…] subjects enter into the research voluntarily […]” and “[…] with 
adequate information” (National Commission 1979), which supports the concepts of information 
transmission and comprehension of the given information.  
 
4.3.2 The fundamental ethical principle behind informed consent: respect of persons or 
autonomy 
 
Apart from the three crucial components in the informed consent requirement, “respect towards 
persons” is an ethical principle (cf. “Ethical principles in the discussion of informed consent models 
for the return of findings”) and another important component closely connected to the fundaments 
of informed consent. As previously mentioned, informed consent can be regarded as one application 
of this principle stated in the Belmont Report (National Commission 1979).  
 
The standard way in the literature of research ethics is to interpret the principle of “respect towards 
persons” as the principle of autonomy. In the Belmont Report it is stated that respect towards 
persons refers to “[…] the requirement to acknowledge autonomy and the requirement to protect 
those with diminished autonomy.”  (National Commission 1979)  
 
Hence, if this interpretation is valid, persons should be treated as autonomous agents as far as they 
are individuals “[…] capable of deliberation about personal goals and of acting under the direction 
of such deliberation” (National Commission 1979). Those individuals have the “decisional capacity” 
defined as “ability to perform a task” (Beauchamp & Childress 2009:70) to make their own health 
care decisions (Charland 2011). Lacking informed consent would imply a lack of respect for 
persons and hence, deny the individual’s freedom to act on its own considered judgments.  
 
Information is mandatory to give the possibility to individuals of making considered judgments 
(National Commission 1979). Of course, there are cases in which informed consent is not requisite, 
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such as in research of emergency situations when urgency prevents obtaining informed consent, or 
in research with identifiable human material and data which does not pose physical risks (Emanuel 
2013). Nevertheless, these exceptions cannot be applied to the case of research using WGS/WES 
procedures, since genetic testing in research is not a “trivial” intervention, linked to substantial risk 
and not performed in the context of an emergency situation. This means that informed consent is 
required for research using WGS/WES procedures. Respectively, genetic testing in research is 
impermissible whenever informed consent is not given. 
 
Furthermore, third parties should not be harmed by an intervention. Interventions remain 
impermissible without informed consent even if third partied could benefit from interventions. 
Apart from third parties, even benefits for the individual do not justify an intervention without 
informed consent. Also, a former consent is invalid as soon as an individual changes his/her mind 
about a certain health care intervention. In consequence, the principles of autonomy, beneficence 
and non-maleficence by Beauchamp and Childress (2009) have to be respected for individuals and 
for third parties. 
 
4.3.3 Informed consent for research subjects with lack or impairment of decision-making 
capacity 
 
With respect to the rare diseases genomes project, there could be children or disabled persons tested. 
In order to address the case for research subjects without fully developed decision-making capacity 
(due to age or mental impairments), Eyal (2011) introduces the possibility of a proxy that acts on 
behalf of the research individual. “When the antecedent is inapplicable, for instance, when the 
patient lacks decision-making capacity, similarly spirited rules apply, such as rules delegating 
consent “authority” to the patient's advance directive or proxy.” (Eyal 2011) 
Equally to Eyal’s definition (2011), the protection of those individuals with diminished autonomy is 
demanded, referring to the principle of “respect for persons” (National Commission 1979). 
 
4.3.4 Informed consent process 
 
To understand the informed consent requirement, it is important to analyze the idea of the informed 
consent process, a practical consequence of the informed consent theory. The informed consent 
process is an information exchange including subject recruitment materials, verbal instructions, 
written materials, question and answer sessions and signature documenting consent with date. 
Importantly, the term should not be mistaken as a subject’s signature on the consent form which is 
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only part of process (U.S. Food and Drug Administration (FDA) 2015). The informed consent 
process gives to subjects the opportunity to choose involvement based on information, 
comprehension and voluntariness (McGuire Dunn and Chadwick 2012; NBAC 2001). The aim is to 
assure an individual’s autonomy, meaning that it has not been deceived or coerced (O’Neill 2003). 
The ideal informed consent process is an ongoing process which is not completed prior to the end of 
the study (Chin and Lee 2008).  
 
The informed consent process involves the consent taker reviewing the consent form and all 
information relevant for the study with the participant and assuring the participant’s comprehension 
of the content. The consent taker is supposed to relate all of the important elements of the study, 
including the written information by the research ethics committee (REC) (Chin and Lee 2008). If 
information is not appropriately understood, individuals should not be enrolled in the study, even if 
they are willing to consent. Otherwise the consent is not truly informed. Thus, time and the 
opportunity to ask questions must be always given to the individual, as well as all questions 
concerning the study have to be answered to the participant’s satisfaction. Furthermore, the CIOMS 
guidelines (CIOMS and WHO 2002) prohibit taking informed consent in a language distinct of the 
participant’s language. However, if a witness who does understand the participant’s language is 
present, consent taking can be permitted.  
The informed consent form and patient information sheet (“consent form”) has to be signed before 
the participant takes part in the study, meaning that any procedure related to the study has to be 
performed after the consent. A copy of the consent form must be handed in to the participant.  
 
As part of the informed consent process, there might be occasions where re-consenting is required, 
although the participant already went through the initial interview of informed consent. This is the 
case for instance, if significant changes in the protocol occur which might impact on the 
participant’s willingness to participate in the study and if the risk-benefit profile of the study 
changes due to the data analysis of interim information. A participant is free to refuse and 
discontinue a study at any point in time even if the consent form has been signed prior to re-
consenting at any changes (Chin and Lee 2008). 
 
4.4 Additional definitions  
 
In order to avoid confusion, the following definitions are given concerning terms and concepts that 
are used for the development of an informed consent model in research using WGS/WES 
technologies.  
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Information costs are part of transaction costs that occur in transactions. Costs concern information 
processes, as coming to an agreement with the other party, drawing up a contract etc. (Brigham 
Young University, IS theory 2014). Information costs appear due to the fact that full information 
provision is not available and that information is usually asymmetrically distributed. Costs have to 
be spent in order to reach a common information level (Akbari 2014). Applied to WGS/WES data 
research and the further introduction of the iterative informed consent model, information 
transmission between researchers, counsellors and participants are inevitably linked to costs due to 
the information flow. 
 
Privacy can be considered a guarantee to defend human dignity and integrity (Boustein 1964) 
enhancing personal expression and choice (Schoeman 1992). Privacy is also crucial for intimacy of 
an individual (Gerstin 1978, Inness 1992). According to Bloustein, “inviolate personality” is a 
social value (cf. definition of value) that is protected by privacy. Privacy is the basis for the 
development of meaningful interpersonal relationships (Fried, 1970) and gives individuals the 
possibility to control the access others have to them (Moore 2003). 
 
The term “value” will be used in the traditional sense of intrinsic values “lying at the heart of ethics” 
(Zimmermann 2010). The intrinsic value of something is the value that the thing has “in itself,” or 
“as such”. In contrast, extrinsic values are derivative values and good for the sake of something else 
which is intrinsically good. Referring to consent models, the presented values of each model are the 
pillars the model is built upon. For instance, when the value “autonomy” is undergoing ethical 
analysis of the values composing autonomy, as e.g. financial independence or freedom of decision-
making, (although they might be intrinsic as well) have to be correlated with the covering value 
(Chang 1997).  Eckstein et al. (2014) applies the term “value” to research findings by defining it as 
a normative property “[…] regarding the worth, significance, or utility of a research finding 
(whether subjective or objective)”. Thus, the finding is necessary for a state of affairs that has worth, 
significance of utility. 
 
5. General argument: constructing the iterative feedback model 
 
The iterative feedback model will be constructed on the basis of the outlined scope of the thesis and 
the theoretical framework. In chapter four, characteristics of genomic data and an informed consent 
theory were introduced which will now be applied to the particular case of research using 
WGS/WES procedures by designing an informed consent model. In several steps that follow in the 
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next sections ethical principles, positions and informed consent models for research using 
WGS/WES procedures addressing the disclosure of incidental findings will be carefully weighed, 
evaluated and incorporated in the design of the iterative feedback model.  
 
5.1 Analysis of the iterative feedback model for the return of findings  
 
In order to discuss the obligations of researchers to return findings, it is necessary to clarify the 
extent of this obligation. In other words, the return of findings is often limited by terms and 
concepts like “incidental”, “analytic validity”, “clinical validity”, “clinical utility” or 
“actionability”. However, these terms are used in different ways by different authors, and moreover, 
refer to different cases on which the obligation to return findings is based (Eckstein et al. 2014). 
Referring to the example by Eckstein et al. (2014) – that a lack of clarity about key terms can 
sometimes lead to contrary recommendation for the return of findings – it is of great importance to 
define these terms. Consequently, it should be discussed which findings are mandatory to return 
from an ethical perspective. 
 
5.1.1 Reconstruction of the Presidential Commission’s view on returning findings 
 
The Presidential Commission for the Study of Bioethical Issues report (2013) “Anticipate and 
Communicate: Ethical Management of Incidental and Secondary Findings” recommends to 
demarcate four different kinds of findings which do not fall under the term “primary findings” (cf. 
table 2): “Anticipatable incidental findings” (findings not sought for, but associated with a test or 
procedure), “unanticipatable incidental findings” (findings not sought for and not anticipated, 
giving the current state of scientific knowledge which occur due to the vast amount of data potential 
of WGS/WES), “secondary findings” (findings actively sought for by researchers, but not the 
primary target) and “discovery findings” (being results of a broad or wide-ranging test that was 
intended to reveal anything of interest). “Primary findings”, in contrast, are the results researchers 
actively sought for and are associated with the performed procedure (Presidential Commission 
2013:28-29).  
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Table 2: “Bioethics Commission’s Classification of Individualized Results of Medical Tests”,  
Source: Presidential Commission (2013: 27) 
 
Referring to other authors, the Presidential Commission (2013:79) suggests that researchers’ ethical 
obligation to return incidental or secondary findings depends on features of the findings, which are 
analytical and clinical validity, actionability, clinical or reproductive significance, and the 
seriousness of potential harm. 
The recommendation addressing research findings clearly favours the disclosure of anticipatable 
incidental findings and deliberately sought secondary findings, as well as the possibility of 
disclosing unanticipatable incidental findings. The Presidential Commission furthermore highlights 
that researcher need to respect the wishes of research individuals who want to opt out of receiving 
incidental findings. However, if researchers express ethical objections to not report such findings 
(because the information disclosure could be actionable and life-saving), it is recommended not to 
enrol such individual in research programs (Presidential Commission 2013:87).  
A National Institutes of Health Heart, Lung, and Blood working group agreed in 2010 that 
researchers need to honour participants’ expressed preferences. However, they faced the problem of 
circumstances in which “[...] the evidence of harm is so great, and the potential for reducing the 
harm too little [...]” (Mountain 2013) and decided to override the participants’ wishes on the basis 
of an IRB decision (Presidential Commission 2013:88). For instance, the discovery of a mutation in 
the Huntington’s gene may be a finding whose evidence of harm is great, but potential treatments to 
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reduce harm very limited. Moreover, for certain kinds of research, revealing incidental findings is 
difficult, e.g. for biobank research using de-identified samples. Nevertheless, the Presidential 
Commission (2013:90) recommends giving “strong reasons” in case of undisclosed findings. 
 
If certain findings are predictably associated with a certain type of research (as it surely is in case of 
WGS/WES), researchers have the obligation to anticipate such findings to the most possible extent. 
Subsequently, they are supposed to develop a plan on how to handle anticipatable findings and on 
how to reveal them to research individuals. Likewise, a plan for unaticipatable incidental findings 
must be developed (Presidential Commission 2013:89).  
 
5.1.2 Reconstruction of Eckstein’s et al. view on returning findings 
 
Eckstein et al. (2014) map out current terminology and concepts for the return of findings by a 
systematic literature review. The authors standardize “secondary” and “incidental” findings, central 
terms that they identify, to “secondary findings” following Christenhusz et al. (2013). Eckstein et al. 
(2014) consider the term “secondary findings” to be of utmost importance because of the 
relationship between the findings and research. Usually, valid and valuable findings coming directly 
from research are considered more adequate for disclosure. A common adopted definition of a 
secondary finding is given by Wolf (2008) (in his paper they use the term “incidental finding”): “a 
finding concerning an individual research participant that has potential health or reproductive 
importance and is discovered in the course of conducting research but is beyond the aims of the 
study. This means that the IFs [incidental findings] may be on variables not directly under study and 
may not be anticipated in the research protocol.” 
 
Eckstein et al. (2014) subsequently highlight the core features of such findings, which are “the 
relationship of the findings to research”, the “relevance/importance of the information to research 
participants”, the “foreseeability” and “the manner in which researchers obtained the findings”. 
Regarding these attributes of secondary findings, those findings must show some potential health or 
reproductive importance (Wolf 2008) and must furthermore meet the criteria of scientific validity 
and clinical utility (“relevance of the information”). For instance, if a genetic locus can be 
associated with a rare disease condition, the finding is directly related to the research aim. The 
finding is moreover relevant for the participant who consequently knows about the genetic cause of 
disease. Since the finding is part of the research protocol and it will be actively sought for, it is 
foreseeable. However, there are findings that are not anticipated in the research protocol (otherwise 
they would be considered primary research findings). Findings can be results discovered during the 
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time in which research is ongoing or results discovered by carrying out certain research procedures 
(Eckstein et al. 2014). Referring to an example of secondary finding, it could turn out that a 
participant with a rare disease has an elevated risk to develop breast cancer due to a genetic 
aberration in a known breast cancer gene. In this case, the relationship of the finding to research is 
not direct, the finding is relevant due to risk and prevention possibilities and the finding is 
foreseeable because researchers actively seek for it. However, a finding might not be foreseeable if 
the mutation is located in as yet undiscovered genetic loci for a certain disease condition. In this 
case, the relevance of a finding is linked to future research revealing new phenotype-genotype 
relationships.  
 
The second part of Eckstein et al. (2013) presents a new framework for the disclosure of findings 
and obliterates the distinction between primary and secondary findings. The approach by Eckstein 
et al. (2013) suggests that certain disclosure requirements distinguish findings that should be 
disclosed from findings that should be not disclosed.  Thus, the authors propose three central 
concepts that are considered as basis for an obligation to disclose findings: validity, value, and 
volition. According to the authors, “[...] an obligation to disclose findings exists when findings are 
valid and have value.” Value is defined as “[...] a normative property regarding the worth, 
significance, or utility of a research finding (whether subjective or objective)”. This means that a 
finding has value if it is significant, utile or worthwhile from the individual perspective or in an 
objective context (as e.g. in the clinical setting). The third concept addresses an individual’s 
preference, whether he/she is willing to know about the findings or not. Furthermore, the three 
concepts are only applied to “research findings”, meaning that there must be a relationship to 
research aims and objectives, even if the finding itself is “beyond the aims of the research” or a 
variant of it (Eckstein et al. 2014). Coming back to the example of the rare diseases genomes 
project, findings that are not necessarily related to the rare disease are “beyond the aims of the 
research”. Nonetheless, such findings could be the result of specific recommendations, e.g. 
recommendations given by the ACMG (2013) listing several genes researchers should actively 
search for. In other words, if researchers investigate certain genes that are stated in the protocol or 
respectively in the recommendations, they have to go through all genetic abnormalities of these 
genes. In case an abnormality turns out to be related to a physical condition different from the rare 
disease, the finding is not directly part of the research aims and objectives, but connected to the 
procedure. In contrast, mutations which are neither located in the target genes of the protocol nor 
found in one of the recommended genes would not be considered research findings. 
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Figure 9: “Framework for Analyzing the Ethics of Disclosing Secondary Findings” by Eckstein et al. (2014) 
 
To tie in with the approach given by Eckstein et al (2014), it is important for the further progress of 
an informed consent model for research studies using WGS/WES procedures to clearly set the 
threshold when research findings should be revealed or not. The Presidential Commission (2013) 
recommends to researchers to develop a clear plan how to manage findings, but misses out to give 
clear concepts such plans could be based on. As it will be argued in the next section, the iterative 
feedback model will follow Eckstein et al. (2014), but only partially.  
 
5.1.3 The view of the iterative feedback model on returning findings 
 
In the last two paragraphs I reconstructed the terminology regarding the distinction between several 
types of research findings given by the Presidential Commission (2013) and Eckstein et al. (2014). 
Furthermore, I depicted the model for the return of findings presented in the second part of 
Eckstein’s et al. (2014) paper.  In this paragraph I show how the iterative feedback model of 
informed consent critically integrates the analysis of the two major positions available for the 
ethical obligation of returning findings. 
Following the definitions given by the Presidential Commission (2013), the term “incidental 
findings” will be used in the sense of anticipatable and unanticipatable incidental findings which 
will be both included in the consent model (cf. Table 3). Furthermore, I follow Eckstein et al. (2014) 
by not differentiating between secondary findings and incidental findings, as anticipatable 
incidental and secondary findings are both related to the research project, its procedures, methods 
and aims (“to find something you must on some level search for it” (Christenhusz et al. 2013)). This 
means if the researcher anticipates findings in advance of the study conduct, the difference (given 
by the Presidential Commission (2013)) between “actively seeking for findings” and “certainly 
discovering findings” leads to the same outcome: findings that are foreseeable or anticipatable 
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before the research study is conducted.  In contrast, unanticipatable incidental findings are not 
related to the findings researchers primarily seek for. This type of finding are of importance for the 
iterative feedback model, as it will be also focused on future research discoveries which researchers 
do not aim for at the very outset of a research study. Unanticipatable incidental findings can occur 
due to the vast data potential of WGS/WES sequencing technologies. Hence, these findings can be 
considered a particular characteristic of WGS/WES data and its data heterogeneity.  
 
Incidental findings, including anticipatable and unanticipatable findings, need to meet the standard 
of analytical validity regarding a certain test procedure to be considered research findings (even 
though 100% accuracy cannot be reached, cf. chapter two: “Technical validity: specificity and 
sensitivity of genetic tests”). Furthermore, following Eckstein et al. (2014), findings should be 
revealed depending on the criterion of volition warranting participants’ preferences to know about 
certain genetic dispositions (MRCT Center Harvard 2015). Also, including the criterion of personal 
utility, this thesis focuses on the research participants’ interest to know about findings which 
possibly affect health and reproductive decisions. This means that it will not only be focused on 
findings that are actionable in a narrow sense or fulfill clinical utility. According to Eckstein et al 
(2014), findings can be valuable even though they might not be valuable in terms of clinical and 
personal actions. The authors refer to an “indirect non-clinical value” of findings which means that 
participants may value genetic findings for intrinsic reasons. For instance, a finding could 
contribute to a “[…] greater understanding of ethnic, cultural and/or personal identity and heritage.” 
(Eckstein et al. 2014). Hence, value as a “[…] normative property regarding the worth, significance, 
or utility of a finding […]” (Eckstein et al. 2014) must be considered in a certain context. In order to 
give significance, utility and worth to a finding, the individual background and circumstances of a 
research participant must be taken into consideration.  
  
To sum up, the iterative model defends that all types of findings that affect health and reproduction, 
including anticipatable and unanticipatable incidental findings, even though they are not actionable 
in a narrow sense (e.g. mutations in the Huntington’s gene), should be disclosed, as far as the 
participant is willing to know about them. The threshold set for the disclosure of incidental findings 
in the thesis framework refers to the “3V” (validity, value and volition) framework by Eckstein et al. 
(2014). In other words, research findings that are valid, valuable and volitional should be disclosed 
to research participants.  
However, in case of a research participant’s preference not to know about actionable and lifesaving 
findings, I agree with the recommendation by the Presidential Commission (2013) not to enroll such 
participants in a research study. This is due to the ethical dilemma a researcher faces if he/she is 
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supposed not to reveal information even though treatment or prevention might be available to 
improve the participant’s outcome. 
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 Presidential 
Commission for the 
Study of Bioethical 
Issues (2013) 
Eckstein et al. 
(2014) 
Fist part 
Eckstein et al. 
(2014) 
Second part 
Holzer (2015) 
iterative informed 
consent model 
Primary 
findings 
Findings researchers 
deliberately seek for  
Findings researchers 
deliberately seek for 
The second part of 
Eckstein et al. 
(2013) obliterates 
the distinction 
between primary 
and secondary 
findings of the first 
part. 
 
 
 
Main classification 
of findings:  
 
- Findings that 
fulfil 3V 
(should be 
disclosed) 
 
- Findings do 
not fulfil 3V, 
(should not be 
discloses) 
 
the 3V  only apply 
to “research 
findings”, meaning 
findings related to 
research aims and 
objectives, 
Findings researchers 
deliberately seek for  
Secondary 
findings 
Is not focus of research, 
but researchers actively 
seek for 
Findings with 
potential health or 
reproductive 
importance 
 
 
 
Secondary findings are 
considered 
anticipatable incidental 
findings  
Incidental 
findings 
Anti-
cipatable 
Associated with the 
procedure, but not aim of 
research 
Central terms 
“secondary” and 
“incidental” 
findings are 
standardized to 
“secondary 
findings”, following 
Christenhusz et al. 
(2013). 
- findings that are 
not primary aim 
of research, but 
known that 
associated with 
the test procedure 
and certainly 
discovered 
(anticipated in the 
research protocol) 
- recommended to 
seek for by expert 
commission (e.g. 
ACMG) 
- disclosure if 3V 
fulfilled 
Incidental 
finding 
Unanti- 
cipatable 
Result not known to be 
associated with the test 
procedure 
 - not anticipated in 
research protocol 
- not known to be 
associated with 
the test procedure 
- disclosure if 3V 
fulfilled 
 
Table 3: “Comparison of the classification of research findings by the Presidential Commission (2013), Eckstein et al. 
(2014) and Holzer (2015)” 
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5.2 Ethical principles in the discussion of informed consent models for the return of 
findings 
 
The management of findings arising in a research context is generally based on the traditional 
research ethics principles (Presidential Commission 2013:86). As presented in many theoretical 
frameworks describing and introducing informed consent models, it is necessary to present ethical 
principles in order to evaluate the presented models (e.g. Appelbaum et al. 2014). A range of ethical 
principles has been proposed to support informed consent and the return of incidental findings. 
However, I will present a selection of principles by focusing on those stated by Beauchamp and 
Childress (2009) and in the Belmont Report (National Commission 1979). These principles will be 
considered crucial components in the context of WGS/WES data revealing of incidental findings. 
 
Especially in the new field of research on genetic data, it is always dealt with the delicate topic of 
racism, discrimination, and eugenics that showed us in recent history the possible consequences of 
missing autonomy. Thus, the stated principles are generally recognized as a minimum demand of 
the researcher’s ethical obligations (Appelbaum et al. 2014:29) to minimize harms history taught us.  
 
With respect to the possible implementation of the suggested iterative feedback model, the four 
principles “autonomy”, “beneficence”, “non-maleficence” and “justice” by Beauchamp and 
Childress are complemented by “practicality” (Appelbaum et al. 2014), a principle that is closely 
linked to “cost-effectiveness”. Furthermore, the principle of “intellectual freedom and responsibility” 
(Presidental Comission 2013) undergoes ethical analysis. 
 
5.2.1 Standard bioethical principles in the discussion of the return of findings 
 
Autonomy 
 
Autonomy is usually understood as governance over one’s own agency. According to Beauchamp 
and Childress, “The autonomous individual acts freely in accordance with a self-chosen plan, 
analogous to the way an independent government manages its territories and establishes its policies” 
(2009: 99-100). This self-governance is free from controlling interference by others and has to grant 
adequate understanding, so that meaningful choice is enabled (Beauchamp and Childress 2009). 
The justification of the autonomy concept grounds in the assumption that self-rule is a central good 
in our lives (Eyal 2011), promoting our ultimate goals and thus defines how well our lives go 
(Dworkin 1988). Applied to the discussion of returning findings of WGS/WES procedures used in 
research settings, the understanding of autonomy as self-governance implies that the “narrow” 
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understanding, as e.g. the maximization of choice options a participant has by selecting the level of 
research participation on their own (Kaye et al. 2012 and Hallowell et al. 2014), is rather short-
sighted. The “broad” understanding of autonomy is based on an intelligible communicative process 
that is mandatory to ensure meaningful choices for the individual (Manson and O’Neill 2007, 
Holzer and Mastroleo 2014). This process necessarily contains information disclosure; full 
comprehension and voluntariness (cf. NBAC 1995). What we will call the “broad understanding of 
autonomy” is mostly mentioned in the literature as a major guiding principle named “respect for 
persons” (National Commission 1979). The principle contains the demand of an autonomous ability 
to identify personal preferences, act on the own desires, and direct the course of one’s life. It can be 
interpreted as “[…] freedom from limitation that prevent meaningful choice and encompasses 
dignity and the right to available information even if it does not affect a person’s choice” 
(Presidential Commission 2013).  
 
Beneficence and non-maleficence 
 
The principles of beneficence and non-maleficence (Beauchamp and Childress 2009) are crucial 
principles in research settings. It is necessary to balance possible benefits and risks for an individual 
participating in research projects. Risk, as I will understand it, is a probability or threat of damage, 
injury, loss, or any other negative outcome that is caused by an intervention, and that may be not 
avoided through preventive measures. Risks should never extend possible benefits and harms must 
be minimized. Since all treatments imply at least a minimal level of risk, it should not be 
disproportionate to the benefits of a given treatment. It should be emphasized that (ex ante) 
potential benefits comprise “subjective” or “personal benefits” (cf. “personal utility”), as well as 
benefits that can be linked to clinical utility. For instance, the discovery of a new gene mutation in 
rare diseases can be a benefit in itself for the research subject due to the better understanding of 
disease conditions, but is not necessarily correlated with a better clinical outcome. Furthermore, I 
want to include the principle of beneficence when it specifically refers to public beneficence 
supporting society in the pursuit of public benefit, while minimizing personal and public harm 
(Bioethics Commission 2010). The concept of public benefit includes clinicians, patients, 
researchers, participants, sponsors and other stakeholders associated with research using WGS/WES 
procedures.  
The Belmont Report states similarly, that the principle of beneficence is required in the research 
context. Beneficent actions, including non-maleficent actions, are understood in the sense to do no 
harm and maximize possible benefits and minimize possible harms (National Commission 1979). 
Furthermore, the Hippocratic maxim “to abstain from doing harm” is considered a crucial principle 
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and obligation of medical ethics. The obligation of beneficence can be put in the context of 
particular research projects, as well as in a general context of long term benefits (such as 
improvement of knowledge and medical treatments) for society (National Commission 1979). 
 
Justice 
 
The principle of justice (Beauchamp and Childress 2009) addresses the distribution problem of 
scarce resources in the health sector (Calman 1994). Individuals in similar positions should be 
treated in a similar way, as public health services show public good characteristics and must be 
shared equally among all individuals of the community (Goldstein and Pauly 1976). Justice requires 
that ethically similar cases are treated in a same way. The principle of justice contains furthermore 
the claim that benefits and burdens of an enterprise are equally distributed among those who might 
be affected (Presidential Commission 2013). The notion of justice regarding particular informed 
consent models might change with the progress of time. Access to facilities, as well as to genetic 
counselling can expand and goes hand in hand with the technological progress (Niedringhaus et al. 
2011). In a similar way, the Belmont report formulates that burdens and benefits should be 
distributed “[…] (1) to each person an equal share, (2) to each person according to individual need, 
(3) to each person according to individual effort, (4) to each person according to societal 
contribution, and (5) to each person according to merit” (National Commission 1979).  
Furthermore, it is impermissible selecting research subjects due to their class, their availability, their 
compromised position, or their manipulability.  
 
5.2.2 Special principles in the discussion of returning findings 
 
Intellectual freedom and responsibility  
 
The principle of intellectual freedom and responsibility (Presidential Commission 2013) supports 
the intellectual exploration propelling scientific progress. Nonetheless, clinicians, researcher and 
other agents must take responsibility for their actions, including their intellectual pursuits. Thus, the 
principle of intellectual freedom and responsibility counters the technological imperative: “The 
mere fact that something new can be done does not mean it ought to be done” (Presidential 
Commission 2013:31). 
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Practicality 
 
The principle of practicality (Appelbaum et al. 2014) tries to evaluate if an informed consent 
model is able to withstand the demands of the model’s practical realization (e.g. if the needed 
facilities are available, as online access, outsourced genetic counseling etc.). First and foremost, 
practicality seems to be a pragmatic principle focusing on the implementation opportunities of 
informed consent models. However, it can be argued that practicality can be considered as an 
ethical principle, as far as the principle of justice comes into play. Under the condition of scarce 
resources, consent models that are able to grant broader access to health care services for 
individuals, are more suitable to the principle of justice.  
 
The criterion of cost-effectiveness should also be considered in the scope of practicality. Cost 
effectiveness (Phillips 2009) measures health interventions in a representative monetary value. Its 
analysis comprises techniques of economic evaluation (NICE 2014). Cost-effective analysis (e.g. 
cost-utility, cost-benefit analysis) is an economic analysis in which consequences of different 
interventions are measured using a single outcome (e.g. life years gained, deaths avoided etc.). It is 
required to choose the optimal intervention regarding the outcome. Society should seek cost-
effective ways for health care provision in order to warrant all individuals the access to adequate 
and affordable services to meet basic health care needs, as demanded by the principle of justice 
(Presidential Commission 2013:63). Applied to WGS/WES counselling, the gain of counselling and 
return of incidental findings have to be “weighed” together with the costs that arise in this context. 
Models showing a high benefit-cost ratio are preferable according to the cost-effective analysis, but 
cannot be considered independently of other moral considerations. 
Depending on the cost effectiveness, the implementation of an informed consent model is 
sustainable or not which makes it a pragmatic and not an ethical argument. Usually, cost-effective 
informed consent models are more realizable in a health care system, as costs are low compared to 
other models of low cost-effectiveness. However, this is not necessarily the case, because cost-
effective models could be also costly models with a very favorable outcome showing a high benefit-
cost ratio. It is also crucial to mention that the benefit-cost ratio strongly depends on the costs that 
are included in the cost-benefit analysis and whether costs and benefits for future generations are 
included. Moreover, it can be difficult to measure benefits and costs especially if they gain in 
importance in the future. Cost reduction by maintaining the benefits may be reached due to reduced 
bureaucracy in administration posts, advances in technology and fewer expenses for infrastructure 
in the public health sector (Enthoven 1988). 
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5.3 The analysis of the iterative model in the light of standard informed consent models 
for disclosure of incidental findings 
 
When designing an informed consent model, the model should be guided by an informed consent 
theory. Informed consent models try to apply an ideal consent theory in practical terms by 
specifying models (cf. Table 4). In the following section, I will introduce four informed consent 
models for the disclosure of genetic research findings following Appelbaum et al. (2014) who 
identified prototypic informed consent models based on a literature research. Namely, those models 
are (1) the traditional informed consent, (2) the staged consent, (3) the mandatory return and (4) the 
outsourcing informed consent. 
 
The intention is to challenge the models with ethical principles worked out in the previous section, 
as well as to evaluate their respective advantages principles in a particular context. Importantly, 
informed consent theories constitute a justification for the particular design of a consent model. 
After the evaluation of the models, this section will introduce another informed consent model, the 
dynamic informed consent, which constitutes in conjunction with the traditional consent model the 
basis for the iterative feedback model. Differently to the other standard models that will be 
discussed, the dynamic feedback model has been developed for the research setting of biobanking. 
Nevertheless, it comprehends a dynamic informed consent process which makes it applicable to the 
setting of research studies using WGS/WES procedures which are conducted over long time periods 
and deal with “non-exhaustible” data.  
In a next step, I will try to weigh arguments in favor and against these consent models. The last step 
consists in the development of a new consent model, the iterative feedback model. It will be argued 
that this model is more appropriate for research studies using WGS/WES procedures and the 
disclosure of incidental findings.  
 
Traditional consent model 
 
The (1) traditional consent model favors participants receiving all information about possible 
incidental findings prior to deciding whether they enroll in a research study. Ideally, a discussion 
with the participant would cover the characteristics, likelihood and categories of relevant incidental 
findings, the options for participants for returning some or none of the findings as well as the 
possible impact on third parties and confidentiality issues. After the discussion, the patient chooses 
which findings should be revealed and which not (Appelbaum et al. 2014:25).  
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Stage consent model 
 
In the (2) staged consent, participants receive findings, if there are any, after they occur. Informed 
consent is obtained in stages, with a short discussion on incidental findings at the beginning, and a 
more extended consent process if and when reportable results are available (Appelbaum et al. 
2014:26).   
 
Mandatory return model 
 
The (3) mandatory return model advocates that participants agree at the beginning of the research 
project on receiving specific incidental findings that the researcher chooses or that are suggested by 
certain commissions. For instance, the American College of Medical Genetics and Genomics 
(ACMG) recommends the disclosure of specific findings related to certain disease categories 
regardless of the aim of the research study (Green et al. 2013).  
 
Outsourcing model 
 
The (4) outsourcing model suggests to give the participant his/her raw genetic data. Interpretation of 
data and incidental findings is then provided by an external service (Appelbaum et al. 2014:28).  
 
5.3.1 Evaluation of standard informed consent models using ethical principles 
 
After having shortly depicted these consent models, the next step is to evaluate their ethical validity 
by applying ethical principles (cf. “Standard bioethical principles in the discussion of returning 
findings”, “Special principles in the discussion of returning findings”), namely “autonomy”, 
“beneficence and non-maleficence”, “justice”, “intellectual freedom and responsibility”, as well as 
the pragmatic principle of “practicality”.  
 
Autonomy 
 
In this paragraph, the core criteria of autonomy, “act on the own considered judgments”, “full 
transmission of relevant information”, “full comprehension” and “voluntariness”, will be applied to 
the above described models.  
In staged consenting models, participants receive information about incidental findings later, as they 
arise. This skips the information process prior to research participation. Hence, at the point in time 
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of decision making whether to participate in a study or not, full comprehension and thus, an auton-
omous consent cannot be achieved. However, a more detailed information on incidental findings 
can be discussed at a later point in time (Appelbaum et al. 2014:24) which contributes at least to 
comprehension in the course of the research study, even though an informed decision for the partic-
ipation to enroll in the study is still missing. 
The mandatory return model leaves the obligation to feedback incidental findings completely in the 
researcher’s hands. Participants agree initially to receive specified incidental findings, transferring 
the task of decision making to the researcher. Therefore, this model of return of incidental findings 
does not respect the individual freedom of the participant to act on own considered judgments.  
In consent outsourcing models, the raw genetic data material is given to participants who then could 
make use of second services analyzing the data. Full transmission of relevant information and full 
comprehension strongly depends on the quality of the external service. Thus, it can be argued that it 
is part of the researchers’ obligation to assure that full comprehension and full transmission of rele-
vant information are granted. Nevertheless, the choice to select findings the participant wants to 
know about is not rejected.  
Finally, the traditional consent model is the only model suggested by Appelbaum et al. (2014) that 
offers information on incidental findings prior to research participation. Therefore, it can be consid-
ered the model which fits best the demanded criteria of full comprehension, full transmission of rel-
evant information and voluntariness in the process of decision making. 
 
Beneficence and Non-maleficence 
 
Beneficence and non-maleficence are principles that are closely connected to other ethical and 
pragmatic considerations. Depending on the understanding of benefits and risks, the principles can 
comprehend personal or public benefits/risks. None of the four models can avoid possible harm to 
the participants because there will be always the risk that the disclosure of incidental findings caus-
es psychological harm. Especially the staged consent model that does not discuss findings prior to 
research participation can cause tremendous harm if participants are not prepared to receive the in-
formation of incidental findings. In contrast, the traditional model makes the intent to grant minimi-
zation of harm due to the option to discuss the findings that are revealed to the participant.  
Benefits can be created when findings are disclosed regarding clinical and personal utility and the 
value of findings. Again, the traditional model can be considered the best attempt to reveal all the 
findings that could be utile and valuable for the participant, since the participants can utter his/her 
preferences for particular findings. 
The outsourcing model does not necessarily cause harm if the participant does not hire interpreta-
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tion services. However, possible benefits would not be disclosed either regarding this scenario. 
 
Justice  
 
The principle of justice demands that persons in similar cases are treated in a similar way. Further-
more, public health resources should be shared equally among all individuals of the community 
(Goldstein and Pauly 1976). Regarding the outsourcing model, a problem arises when focusing on 
the principle of justice. As Appelbaum et al. (2014:29) explain, potentially actionable data that 
could be disclosed by the researchers is not necessarily accessed due to missing interpretive services. 
Also, the costs for the disclosure remain outsourced which means that some participants may not be 
able to afford the services. In this case, participants from lower classes would be systematically ex-
cluded from interpretation services. With respect to the traditional model, it can be argued that an 
intense information process prior to research participation consumes resources that could be invest-
ed in other sectors of the health care system. This issue will be addressed in detail in the section on 
objections to the iterative feedback model and discussed together with the problem of cost-
effectiveness. 
 
Intellectual freedom and responsibility  
 
The principle of intellectual freedom and responsibility supports the intellectual exploration and 
scientific progress. The second aspect (responsibility) demands researchers to assure that they take 
on responsibility for their intellectual pursuits. It can be argued that the traditional model hampers 
medical progress due to a long and complex communication process. Sheehan argues that more 
standardized consent taking saves resources that could be genuinely spent on the research enterprise 
(Sheehan 2011). However, even though the outsourcing model avoids in particular the reallocation 
of resources from the research study to the communication process with the participant, it can be 
objected that researchers do not assume responsibility to share information with the participants in 
this model.  
 
Practicality  
 
The pragmatic principle of practicality is not primary subject to the ethical analysis, but useful to 
consider with regard to the implementation possibilities of informed consent models. Appelbaum et 
al. (2014) put emphasis on practicality when evaluating the models (Table 4), as the outlined ad-
vantages and disadvantages clearly refer to the practical realization of the models.  
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First of all, the traditional consent model comprises a long and complex information process which 
makes the implementation of the model difficult (time and monetary resources have to be available). 
Additionally, since decision-making is in the participant’s hands, there is no exact plan how to deal 
with preferences of the participant that may change after the initial consent. The staged consent and 
the mandatory return model comprehend a less time consuming discussion prior to the initial con-
sent. Detailed discussions are linked to concrete findings. Thus, resources are well invested (just 
spent in case of valuable results for the participant). Also, regarding the mandatory return model, 
obligations for researchers to feedback findings are clearly defined and can be standardized more 
easily. Nonetheless, Appelbaum et al. (2014:24) state that re-contacting participants could add to a 
long and burdensome process, in particular because re-contacting depends on the availability of 
funding and on a system of communicating with participants. From the researcher’s perspective, the 
outsourcing model might be the most convenient one, since it does not create a burden for research-
ers to deal with incidental findings. However, the model only works if interpretive genetic services 
are available in a health care system (Appelbaum et al. 2014:29). In case of the availability of such 
services and sufficient coverage by a health care insurance, health care resources must be spent for 
the interpretation of data. 
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                 Table 4: “Prototypical informed consent models”, source: Appelbaum et al. (2014) 
 
5.3.2 Dynamic consent model 
 
After the principle evaluation of standard informed consent models in the previous section, I will 
introduce a model that serves as a template for the further development of the iterative feedback 
model for research studies using WGS/WES procedures. Assuming that the participant's autonomy 
is irrevocable, a consent model called “dynamic consent” has been developed in the context of 
biobank research which enhances autonomy by offering participants the ability to access their 
genetic data personally (Steinsbekk et al. 2013). Furthermore, participants can actively participate 
in the research community of biobanks. Consent taking is a dynamic process, which means that any 
new research study using the already collected data demands new informed consent taking 
(Steinsbekk et al. 2013). The Ensuring Consent and Revocation (EnCoRe) project (EnCoRe 2014) 
has recently demonstrated how this model could be implemented. As part of this project, a web-
based platform with an interface allows research participants to have an interactive relationship with 
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the research community. However, although the interactive communication process optimally 
transfers benefits to the participants and autonomy is granted via a continuous dialogue within the 
research community, it can be objected that re-consenting even for minor changes in a research 
protocols might lead to complications regarding the possibility that research studies are blocked by 
participants opting out. In this regard, the ethical review of research projects becomes 
individualized. Control of research projects and responsibilities are shifted from researchers and 
research ethics committees to participants due to their involvement in research projects (Steinsbekk 
et al. 2013). On the other hand, this can also be considered as enrichment for the democratic 
processes in science, ensuring a socially robust knowledge production (Steinsbekk et al. 2013). 
Regarding the practicality of the model, problems could arise because online platforms and the 
facilities to coordinate the participant’s involvement have to be available to implement the dynamic 
consent model. Nevertheless, these possible problems could be solved by future improvements of 
the health care service. 
 
Drawing a conclusion from the analysis of the discussed informed consent models by applying 
ethical principles, the most important values and concepts for the design of a consent model should 
address the minimization of resource consumption, the autonomy of the participant, the prevention 
of harm, the disclosure of beneficial information, the assumption of responsibility by the research 
body and equal access to interpretation services.   
When designing a consent model for research studies using WGS/WES procedures with the focus 
on the disclosure of incidental findings, the advantages and disadvantage of the mentioned consent 
models, as well as the most common values and ethical principles discussed should be taken into 
account.  
 
5.4 The iterative model construction: a first argument in favour of a traditional, non-
staged informed consent for research using WGS/WES 
 
As explained in the theoretical groundwork of this thesis, genomic information constitutes a very 
special type of information (cf. Box 1). Namely, heterogeneity, irreversibility, connectedness to 
relatives and off-spring and uncertainty underlie the specification and design of an informed 
consent model. It is important to consider these characteristics accentuating the importance of 
informed consent taking, which is not trivial. Especially irreversibility and connectedness can have 
major impacts on an individual’s psychological health state.  
I will analyze in a first step the specific situation of whole genome data disclosure comprising the 
crucial characteristics of WGS/WES data in order to weigh advantages and disadvantages of the 
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introduced consent models more adequately. The further aim of this section is to develop the basis 
for a model ensuring comprehension and meeting the requirement of autonomy. Autonomy is 
chosen to be the crucial principle in this context since it is the principle which enhances the 
participant’s empowerment and self-governance. It will be argued using the principle of autonomy 
that informed consent in the setting of research studies using WGS/WES procedures must aim for a 
traditional and dynamic consent.  
Also, I want to design a consent model putting emphasis on an information process that should be 
as complete as possible (including full transmission of relevant information and full comprehension 
which will be explained in more detail) prior to the study enrollment. In consequence, I desist from 
the staged and mandatory return model because the models lack the transmission of relevant 
information to grant participant’s autonomous choice. In case of the mandatory return model, the 
participant’s option of self-governance is completely undermined.  It should also be taken into 
consideration that findings can reveal irreversible information about very unfavorable health states 
which moreover impacts on the participant’s family, one main reason to involve the participant in 
the information and decision process. 
 
Mainly, it should be asked, how pros and cons of the introduced consent models are weighed. One 
way to evaluate this is how different consent models comply with the basics of informed consent 
requirement as analyzed in section “Informed consent in research using WGS/WES: (1) full 
transmission of relevant information, (2) comprehension and (3) voluntariness. 
 
Information transmission 
 
Since information may be very important to the participant’s future and even to his family and 
descendants, it should be assured that the participant is fully aware of these consequences. 
According to the assumptions regarding the characteristics of WGS/WES data (cf. Box 1: 
heterogeneity, irreversibility, connectedness, uncertainty), the traditional and dynamic consent seem 
to be a more appropriate approaches than a staged, mandatory return or outsourcing consent. In 
other words, delicate and very individual information may ask for a more personal consent process.  
 
Comprehension 
 
In order to make the revealed information more understandable, a less standardized initial informed 
consent, as well as a continuous communication process on complex issues addresses better the 
demand of full comprehension by the participant. Models giving participants full and unlimited 
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freedom to reign over their data like in the outsourcing model undermine the criterion of 
comprehension and thus, do not fulfill the requirements of autonomy in its “broad” conception since 
meaningful choices always depend on a comprehension process where several arguments are 
critically weighed. The outsourcing model would indeed correspond to the “narrow” understanding 
of autonomy which refers to the maximization of choice options (Kaye et al. 2012 and Hallowell et 
al. 2014). However, as argued before, I adopt the “broad” conception of autonomy which is based 
on an intelligible communicative process that is mandatory to ensure meaningful choices for an 
individual (Manson and O’Neill 2007, Holzer and Mastroleo 2014).   
 
Voluntariness 
 
Withdrawing the participant completely from accessing very “personal” (cf. Box 1) information 
does not meet the demand of autonomy nor the right to profit from possible benefits (Wright et al. 
2011). With regard to data heterogeneity, it is difficult from the researchers’ perspective to predict 
firstly, what kind of findings and disease categories should be revealed and secondly, what kind of 
findings contribute to harm and benefits from the participant’s view point. Therefore, it seems to be 
prudent to involve participants as much as possible in the process of decision making in which 
he/she has the chance to utter and rethink the own preferences based on the information that is 
given to him/her, similarly to the dynamic consent. 
 
The only way to respect autonomy of individuals is the implementation of an appropriate informed 
consent process granting (1) full transmission of relevant information, (2) full comprehension and 
(3) voluntariness. As I will argue in the next section, this can  only be achieved by implementing 
genetic counselling which I will understand as a personal and individualized communication 
process.  Based on my argumentation, genetic counselling should be a mandatory element prior to 
research participation using WGS/WES procedures and cannot be skipped. Dealing explicitly with 
incidental findings, a more profound counselling process might be demanded than in case of 
counselling on primary findings. Incidental findings –per definition– are not directly related to the 
research aims and objectives. For instance, if a research project is dedicated to the investigation of 
candidate genes for rare diseases and the participant has already developed the disease and it turns 
out that he/she may show an elevated  risk to develop a (different) neurological disease in the future, 
such a finding could  have an even greater impact on his/her psychological health.  
 
In conclusion, if we want to implement the principle of autonomy in research using WGS/WES, and 
given that genetic data exhibits characteristics as heterogeneity, uncertainty, connectedness to third 
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parties and irreversibility of genetic data – which means that genetic information is individual and 
delicate for participants – an informed consent model should carefully transmit information in an 
extended comprehension process prior to the participation in a research study using WGS/WES 
procedures. In this regard, the iterative feedback model presented in the next step is based on a 
traditional and dynamic consent and refrains from the staged, mandatory return and outsourcing 
models. 
 
5.5 The iterative feedback model: the final argument 
 
The iterative feedback model is a traditional, non-staged model of informed consent including an 
extended and most complete counselling process. One of the main ideas of the iterative model is 
that all relevant information (without mentally overloading individuals) should be transmitted 
during the informed consent process. By taking up the “dynamic” idea of the dynamic consent 
model and applying it to the iterative feedback model, the communication process with the 
participants is not interrupted after the first discussion, implying that changed preferences can be 
communicated. 
 
The “iterative feedback model” is based on a continuous communication process between 
counsellor and participant. I define “counsellor” as the person who communicates information and 
whose task is not necessarily to conduct the research project.  However, this will be specified in 
more detail in the section on “communication process between and counsellor and researcher”. 
Hence, the informed consent process can be considered a holistic or integral process including 
counselling prior to genomic data collection and counseling on incidental findings after the onset of 
a research project. I will call the time of information exchange between counsellor and participant 
“counselling unit”. The counsellor is supposedly a geneticist or a qualified physician working at the 
institution. Every finding related to the research project should be revealed by the counsellor if the 
participant wants to know about it, as long as the privacy of other research participants is not 
violated (WHO 2014). Counsellors are supposed to raise awareness of the fact that incidental 
findings can be discovered in whole genome data analysis. The consent process should furthermore 
convey “[…] the scope of the findings and to whom the findings will be communicated” 
(Presidential Commission 2012).  
Counselling prior to participation should therefore ensure that the participant understands possible 
harms and benefits related with data collection and further disclosure. Subsequent counselling units 
will be necessary as soon as a research finding appears that fulfills the disclosure criteria (c.f. “The 
view of the iterative feedback model on returning findings”) of volition, value and validity. In this 
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respect, counselling grants full comprehension of possible harms and benefits in every single case 
of additional valid, valuable and volitional (3V) research findings.  This refers also to future 
unanticipatable incidental findings which can arise e.g. due to improvement in knowledge or 
changes in recommendation guidelines. Differently to the dynamic model in which participants are 
enabled to actively participate in a research community via online platforms, personal and 
continuous (“iterative”) counselling is ensured. The dynamic informed consent offers a full 
involvement in the research project by the suggested online platform where participants stay in 
touch with the research community, but lacks a structured and guided explanation processes (on 
incidental findings).  
 
6. The iterative feedback model and its implementation into health practice 
 
Box 2 shows crucial steps in the informed consent process of the iterative feedback model. It should 
be emphasized that the information transfer exhibits an interactive talk between counsellor and 
participant, supported and underlined by the possibility to ask questions. The whole process needs 
time to grant full comprehension and a voluntary decision making by the participant. Importantly, 
full comprehension can be granted after the first counselling unit, but should not be expected in all 
cases. Comprehension is a function dependent on the variable of time. 
 
Box 2 
 
Crucial steps in the informed consent process – the iterative feedback model 
 Interview  
 Transfer of essential information on the research project, premises, procedures, 
possible benefits and harms  
 Opportunity to ask questions for research participants 
 Informed consent is evidenced by signature of informed consent document 
 Communication and dissemination of summary research results to research individual 
 New counseling unit (on more specific information) 
 Incidental research findings fulfilling the criteria of validity, value and volition (“3V”) 
after the disclosure of primary research results imply a new counseling unit 
 New counseling unit (on more specific information) 
 
 
First of all, the counsellor is supposed to discuss the primary findings of a research study the 
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individual is enrolled in. Once an incidental research finding that fulfills the “3V” framework is at 
hand, the counsellor should re-contact the participant. It should be mentioned that the “value” that is 
attributed to a findings strongly depends on the counselling process - the dialogue between 
counsellor and participant. As mentioned before, value is a normative property regarding 
significance, worth or utility of a finding (Eckstein et al. 2014) which can be only established in an 
individual context. Thus, in order to give significance, utility and worth to a finding (Eckstein et al. 
2014), the perspectives of counsellor and especially research participant must be taken into account. 
This can only be achieved by a communicative exchange of different perspectives. 
 
However, the right to refuse to attend a new counselling unit at any point in time must always be 
given to the participant, as similarly demanded prior to the participation in a research study (World 
Medical Association 2013, §26). The process of information transmission is taken up again and can 
be deepened by focusing on new aspects of particular incidental findings. In consequence, the 
communication of individual results comprehends specific results of the study and incidental 
findings of the participant (MRCT Center Harvard 2015). 
 
A possible procedure might be that the counsellor initiates a personalized genetic test in order to 
correctly approve the finding in the participant’s personal case. In this way, the counsellor who 
stays in close contact with the participant is the responsible institution for information disclosure.  
 
6.1 Communication process between researcher and counsellor  
 
Firstly, it should be mentioned that counsellor and researcher are not necessarily distinct entities 
(Hallowell et al. 2014). Since the boundaries between research and genetic counselling nowadays 
become more and more blurred (Hallowell et al. 2014:2), researcher and counsellor are often the 
same person. 
 
In order to have a more detailed glance at the counsellor’s task, I will introduce the process of 
information transfer between researchers and counselors which takes place prior to the information 
disclosure to the participant. As Figure 10 depicts, for the participant relevant data is contained in 
three types of databases of genetic variants and disease associations that I construct to exemplify 
relevant data containing individual, public, current and “future” knowledge. Introducing the 
category data of “future” knowledge, I refer to unanticipatable findings. In the course of scientific 
advance, there can appear new phenotype-genotype associations which can be of importance for 
participants whose genomic data have been already sequenced in the past, but which are still 
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available in databases. Known phenotype-genotype associations as well as new discoveries of such 
associations are found in the general literature or in public databases (Database 2 and 3). Database 1 
contains the data of the particular participant involved in the study. In a first step, the counsellor 
needs to access the participant’s collected data that is held by the researcher (if researcher and 
counsellor are distinct entities). Furthermore, it has to be checked if there are genetic aberrations of 
the participant matching common aberrations linked to diseases (database 2). For instance, the 
current ACMG recommendations (Green et al. 2013) are found in database 2. Hence, it should be 
sought for mutations in the recommended genes.  This is first and foremost the task of research. In 
an iterative procedure, it has to be screened for newly discovered disease associations either given 
by database 3 or by the research study itself (database 1). For instance, new publications with 
respect to primary and incidental findings should be regularly checked and compared to the 
participant’s genome. Importantly, the search for incidental findings should only be initiated if the 
participant clearly states that he/she wants to know about the type of finding. In case of incidental 
research findings fulfilling the “3V” framework, a new counselling unit is needed (cf. Box 2). In 
order to facilitate the counsellor’s task, software matching data contained in the three databases 
would be an essential tool. 
                
Data Base 2
Known Associations
Literature
Data Base
Data Banks
Data Base 1
Individual Genome
Genome Data base 
of the research 
study
Data Base 3
New Discoveries
Literature Data 
Banks Research 
Data
Communication process between research and counselling
Step 1: check once in Data Base 1 and 2 for relevant 
findings in ind. Genomes
Step 2: check repetitively  in Data Base 1 and 3 for 
relevant variants in individual Genomes
Inform participant
 
Figure 10: “Communication process between research and counselling after data collection” 
 
6.2 Communication process between participants and counsellors 
 
In this paragraph, crucial recommendations in the informed consent process will be outlined by 
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focusing on the suggestions given by the Presidential Commission (2013: Chapter 3 and 4) on the 
ethical management of incidental findings in the clinical and research context. The 
recommendations will subsequently be applied to the case of WGS/WES research and its disclosure 
of incidental findings. 
 
The informed consent process reveals information on procedures related to the research study, risks, 
accuracy of the sequencing method (cf. chapter 2), benefits, alternatives and the participant’s rights 
during the procedure. A special emphasis should be put on the characteristics (cf. theoretical 
framework) of possible WGS/WES finding and the problem of transferring statistical risks to 
individuals (cf. chapter 2). Also, statements on the purpose of the study and confidentiality are 
required elements in the informed consent process. The counsellor is supposed to describe findings 
that are likely to be discovered or findings researchers seek for in the research project. Adequate 
information comprehends the explanation of crucial characteristics of anticipated incidental findings, 
as well as the possibility of unanticipated findings that can arise. Methods of interaction for the 
return of findings can comprise face-to-face meetings, telephone calls, two-way online meetings, a 
dynamic e-mail exchange or other internet based methods. With regard to longitudinal or 
observational studies (e.g. the rare diseases genomes project), it is recommended to share 
publications with the research individuals while furthermore supporting their comprehension of 
research papers via the methods that were explained beforehand (MRCT center at Harvard 2015). 
 
Prior to research enrollment, the counsellor should also convey information about the process for 
disclosing findings, and explain how participants might opt out of receiving specific findings 
(Presidential Commission 2013:87). The Presidential Commission (2013:87) states that individuals 
must not be enrolled in a research study if researchers have ethical objections to allowing 
participants to opt out whether to receive or not information on findings. For instance, if the 
researcher considers it unethical not to reveal an important finding that could be of high clinical 
utility, because a participant opts out this findings prior to research participation, it is legitimate not 
to enroll the participant in the study (Presidential Commission 2013:87). However, according to the 
declaration of Helsinki (World Medical Association, §26), the option to opt out of being informed 
even after the conduct of the research study using WGS/WES procedures, is an essential ethical 
demand. This could bring researchers and counselors in an ethical dilemma.  Comprehensive 
counselling and a sensitive communication process are the only measures to prevent such a problem. 
 
Anticipated incidental finding (e.g. stated in the ACMG recommendations), i.e. researchers actively 
search for, must be explicitly mentioned in the first counselling session. For instance, the counsellor 
84 
could go through all disease categories of importance with respect to the genes that will be 
investigated. Moreover, participants should be asked what kind of findings should be revealed to 
them. Their preferences must always be taken into account and respected (Presidential Commission 
2013:64). The categorization of findings likely to be discovered and the sharing of guidelines on 
this categorization among researchers and counselors could facilitate the information process due to 
standardized counselling protocols issued in the most complete way.  
 
It could moreover be useful for researcher and participants to develop a plan how to manage 
intended primary, anticipated as well as unanticipated incidental findings. The search for 
unanticipatable findings that could be discovered after the onset of a research study due to updates 
of recommendations or extended genetic knowledge should be discussed with the participant in a 
separate counselling unit. In this regard, non-clinical researchers could also assess the expertise of 
clinicians for the discussion with participants, or data from biobanks could support the secondary 
analysis of findings (Presidential Commission 2013:90). 
Moreover, the MRCT Center at Havard (2015) proposes to develop a return of results (ROR) toolkit, 
including a neutral language guide and a useful checklist, containing the crucial information that 
must be transferred in counselling units. While a guidance document addresses basic principles, 
organizational processes, and logistics, the toolkit specifically provides practical examples to 
sponsors and researchers. Furthermore, the work group suggests a check list addressing crucial 
questions and information of importance for the research subject. 
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Recommendations for a “study visit” (counselling session) by the MRCT Center at Harvard (2015): 
                          
Table 5: “Recommendation for study visit”, Source: MRCT Harvard (2015) 
 
With respect to the required paper work in the informed consent process, it is important to present 
the information in an understandable way. Factors, a counsellor has to take into account are the age, 
educational level, the literacy etc. of the potential participant. These tools assure that the content of 
counselling contains the essential components and respect cultural and literacy conditions of 
research individuals. 
 
Special attention should be given to health literacy, “the degree to which individuals have the 
capacity to obtain, process, and understand basic health information and services needed to make 
appropriate health decisions” (U.S. Department of Health and Human Services (HHS) 2010). 
Publicly educating participants about primary and incidental findings in research using WGS/WES 
enables participants to make better informed choices. Especially in low income countries, missing 
education can lead to a reluctant attitude of participants and non-informed choices (Creed-
Kanashiro et al. 2005). For example, materials
2
 could be dispersed via channels including mass, 
digital, and social media. Similarly, the ethical education of researchers and counselors help to 
communicate research aims, findings etc. in a more thoughtful way.  
The education of participants and responsible agents in research and health care should be promoted 
by federal, state, and local public health institutions (Lachance et al. 2010). Since WGS/WES 
procedures have the potential to gain more importance in research practice (cf. chapter two, 
decreasing costs of WGS/WES technologies), educating society about these new technologies could 
                                                 
2
 However, there is not enough evidence that materials facilitate understanding by the research participants. More 
studies are needed to evaluate what type of material could improve comprehension (Grady 2011). 
86 
be facilitated, due to the mere fact that genetic tests become routine practice. 
 
6.3 Overview of the communication process  
 
The iterative feedback model offers an approach in which the counsellor bridges the communication 
process between research subject and researcher (Holzer and Mastroleo 2014). Similarly to the 
dynamic consent (Figure 11
3), the participant’s preferences and values have to be transmitted to the 
research team. Research results are disclosed to the participant via the counsellor. Recognizing that 
much of science happens “bottom-up”, resulting in investigations exhibiting scientific value, the 
iterative model tries to integrate the “top-down” perspective, which means that scientific aspirations 
honor participants’ values and preferences (Might and Miller 2014). The “3V” framework 
specifically addresses both perspectives (bottom-up and top-down) by setting the standards for the 
disclosure of incidental findings to validity (in particular important for scientific aspirations), value 
and volition (which also acknowledge the participant’s view point).  
 
If needed, the system gives the opportunity to establish a decentralized genetic counselling process 
between research institutions and participants, as counselling can be outsourced from research. 
Nevertheless, the iterative model gives room to variation of the researcher-counsellor relationship. 
This means that e.g. both tasks can be attributed to the same person. However, in theory, researchers 
primarily aim to answer research questions, whereas the counsellors should focus on the 
participant’s preferences and values (Hallowell et al. 2014:2). Thus, the tasks of researchers and 
counselors are clearly separated. Nevertheless, researchers/the principal investigators are the party 
taking on main responsibility, as they are directly involved in the research study design and the 
discovery of primary and incidental findings.  
 
                                                 
3
 Importantly, I do not focus on the data use, but on the occurrence and communication of incidental findings. Figure 
11 should give a picture on the information process – however, the content of information is different for the applica-
tion of the iterative model to the case of research studies using WGS/WES procedures. 
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                      Figure 11: “The dynamic model work flow”, Source: Encore project (2012). 
 
6.4 The iterative feedback model applied to the case: the rare diseases genomes project 
revisited 
 
The pillars of the iterative model demand the full disclosure of relevant information, as the 
background of the research study, possible benefits and risks. The counselor is supposed to explain 
the dimension of whole genome data. The presented study of the rare diseases genomes project does 
not only focus on a single preselected gene locus, but investigates a big number of genetic loci and 
thus, has to be considered in the context of GWAS. Due to the extent of the study, the counsellor has 
to detail the possibility of incidental findings that can concern different types of phenotypic 
characteristics. Those characteristics might be of psychological importance, predictive, of high or 
low risk, concern physical diseases or might affect relatives and offspring. It is important that 
participants take a voluntary decision whether to participate or not, as soon as they fully understand 
the given information and know about possible scenarios. The search for certain types of findings is 
only permitted if the participants clearly express the wish to know about findings. As soon as 
research results are available, participants have to be informed and new counselling units can be 
arranged. This leads to an iterative informed consent process based on dialogues, in which 
participants continuously learn about their genetic data.  
 
7. Evaluation of the iterative feedback model  
 
The iterative feedback model meets the principles of autonomy in the sense of self-governance, 
non-maleficence (because it is a controlled process), beneficence (new findings in research can be 
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revealed due to the continuous counseling process), and justice (if the access to counselling services 
does not discriminate on participants’ capacity to pay, e.g. if governmental health care systems 
cover expenses when needed). Furthermore, due to the continuous and ongoing process of 
understanding, a specific as well as an understandable consent is granted. After having 
reconstructed the main arguments for the design of the iterative feedback model, I will analyze in 
the next section the objections that arise when focusing on the practical implementation of the 
model.  
 
7.1 Objections and responses to the iterative informed consent model 
 
Applying informed consent models to a practical setting leads indeed to challenges as far as their 
implementation is concerned. Thus, it is necessary to discuss the most important objection to the 
introduction of the iterative feedback model. Four objections will be presented, namely, “resource 
management”, “therapeutic misconception”, “post-trial counselling”, and “ancillary care obliga-
tions”. Since the iterative feedback model focuses on an extended communication process between 
counsellor and participant over long time periods, the objection addressing the resource consump-
tion may be reasonable and very important for the practical implementation. The performance of 
post-trial counselling also plays a major role in a model advocating continuous counselling. Finally, 
ancillary care and therapeutic misconception constitute objections that are applicable to informed 
consent theories and models in a more general way. Nevertheless, these objections are important in 
the general discussion on informed consent and should be mentioned. In the following paragraphs 
each objection is introduced and described in the context of the iterative feedback model. Moreover, 
possible solution that could counter or weaken the discussed problems will be presented as well.  
 
7.1.1 Resource management 
 
It can be objected that the iterative informed consent process is resource consuming and overworks 
the health system (Hallowell et al. 2014, Sheehan 2011). Therefore, the iterative feedback model 
potentially faces the problem of cost effectiveness. However, it cannot be assumed without evidence 
that the iterative informed consent is not cost-effective, as the benefits of the model can possibly 
exceed the disadvantage of resource consumption. In general, little is known about the cost 
effectiveness of studies especially in the context of the disclosure of incidental findings 
(Presidential Commission 2013:67). Considering cost-effectiveness as an outcome that takes into 
account both the costs and health care benefits of alternative intervention and counselling strategies, 
it is useful to address the issue of health care cost arising when findings are of clinical relevance 
(Presidential Commission 2013:67).  
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Moreover, as the case example of the rare diseases genomes project shows, former health care costs 
prior to the research project can widely exceed the costs related to the project itself (Perdeaux 2013). 
Coming back to the case study, two siblings were involved in a diagnostic process for 20 years 
costing 14,000 pounds (about 21.000 USD) before they participated in the rare diseases genomes 
project which widely exceeded possible counselling costs linked to the project (Perdeaux 2013). 
Furthermore, as found in the literature, the perception of cost burden differs enormously among 
researchers. Some researchers consider costs “too high” and others classify them as “maybe high” 
(Sofaer et al. 2009). This shows that it might be difficult to define costs.   
 
Furthermore, cost-effectiveness can only be seriously taken into account if the parameters of a 
particular research study, health care system and counselling mechanism are known. If the prior aim 
is to protect participants from possible harms and warrant their maximal autonomy in order to 
support the value of self-governance in our society, the iterative informed consent is able to be cost 
effective due to the added value it generates, although it remains resource consuming.   
 
Moreover, counselling teams which are personally supervising participants and communicate 
findings consume fewer resources than the communication process between huge biobanks/research 
institutions and participants (as suggested by the dynamic model), due to reduced bureaucracy in 
smaller counselling institutions (Holzer and Mastroleo 2014). In this case, as an alternative to the 
dynamic consent model, it may not be necessary to provide sophisticated platforms or facilities in 
order to communicate incidental finding to the participant.  
However, information costs due to the communication process between research institutions and 
counselling services remain. Nonetheless, in university hospitals, where care and research are 
closely interconnected, the physicians involved in research activities can, after appropriate training, 
simultaneously perform counselling tasks which could reduce the costs of information transmission 
between the two branches.  
 
As recommended by the Presidential Commission (2012), the task to support studies to evaluate 
proposed frameworks for offering return of findings derived from WGS/WES is attributed to 
funders or sponsors of whole genome sequencing. Funders/sponsors should also support research to 
investigate preferences, values and expectations of the individuals participating in a research study 
(Presidential Commission 2012:6-8). 
Also, in other settings, counselling services could be provided by Clinical Research Organizations 
(CROs) if a research study is executed by a CRO. CROs (e.g. TKL research www.tklresearch.com 
or Accovion www.accovion.com) are third parties that provide allocation services of clinical trials 
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to big pharmaceutical companies. One work field of CROs (cf. e.g. www.richmondpharacology.com) 
focuses on “medical writing” which comprises data editing of participants’ information, drafts of 
consent declarations, documentation sheets for the clinical work flow, and adequate publication of 
collected data and results. This could be extended by counselling services. 
 
 As the circumstances require, supportive online services could help the information transmission 
e.g. by automated messages with short notifications between research and counselling institutions 
revealing information on new research data. The same automated process could be implemented 
between counsellor and participant. 
 
7.1.2 Therapeutic misconception  
 
Another more general objection that can be encountered in the literature of research ethics is called 
therapeutic misconception. With regard to the informed consent process, it is often objected that 
research participants do not understand the essential distinction between research and care and thus, 
fail to make meaningful decisions (Henderson et al. 2007:324). In other words, therapeutic 
misconception is based on the misunderstanding of the difference between the obligations of 
“researchers to participants” and of “physicians to patients”.  
 
In Appelbaum and colleagues’ report from interviews with patients with psychiatric disorders 
(1982), it was shown that research participants were unaware of crucial characteristics of the 
research study design, such as randomization, non-treatment control groups and placebos or double-
blind procedures. The missing capacity of the participants to distinguish between research and 
treatment marked the term “therapeutic misconception”. Henderson et al. (2007) take up this 
misunderstanding that frequently occurs in research studies, by defining therapeutic misconception 
as missing understanding “[…] that the defining purpose of clinical research is to produce 
generalizable knowledge, regardless of whether the subjects enrolled in the trial may potentially 
benefit from the intervention under study or from other aspects of the clinical trial” (Henderson et al. 
2007:1736). This leads to a systematic misunderstanding of the duties that are attributed to 
researchers (which do not necessarily coincide with the duties of physicians in the context of care).  
Furthermore, Henderson et al. specify five crucial points that participants should understand in 
order to not undergo therapeutic misconception (Henderson et al. 2007:1737).  
 
1. It should be understood that the scientific purpose is to generate generalizable knowledge 
and to answer questions about safety and efficacy of interventions. 
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2. Participants in trials need to know that research can imply additional study procedures in 
addition to the intervention.  
3. For interventions in the scope of a study, there is often more uncertainty about risks and 
benefits. 
4. Protocols are usually strict on dose, scheduling etc.. 
5. Clinicians in health care setting provide treatment; in the trial setting they undertake 
research tasks as investigating safety and efficacy of an intervention. 
 
However, it can be argued against the general objection of therapeutic misconception that firstly, 
therapeutic misconception strongly depends on the research setting. Appelbaum et al. (1982) could 
show that therapeutic misconception occurs in the case of patients with psychiatric disorders who 
are enrolled in a trial using randomization, placebo treatment etc.. In contrast, in the context of 
research studies using WGS/WES, participants have to be primarily aware of the possible findings 
that occur in the future. Furthermore, considering GWAS (like e.g. the case study of the rare 
diseases genomes project) as a subarea of research using WGS/WES procedures, participants are 
often not involved in conventional study designs with investigative tools, as randomization, placebo 
treatment etc.. Furthermore, point 2 (additional study procedures to the intervention) and point 4 
(strict protocols and schedules) do not necessarily apply to participants of this type of WGS/WES 
research. However, there might be other settings of research studies using WGS/WES procedures 
where point 2 and 4 clearly apply.  
 
Secondly, with regard to the other points stated by Henderson et al. (2007), the aim of the iterative 
feedback model is exactly to prevent the lack of comprehension by 
1. an iterative process, facilitating full comprehension of research characteristics due to a 
temporally extended communication process; 
2. a communication procedure in which participants are encouraged to ask questions. 
 
Thirdly, the concept of therapeutic misconception can be criticized in itself. In order to differentiate 
the obligations of “researchers to participants” and “physicians to patients” (the assumption 
underlying therapeutic misconception), a difference must exist. It can be contestable whether the 
obligations of researchers and physicians are clearly different or overlapping. 
 
Tying up to the argument of therapeutic misconception, there is another type of misunderstanding 
that can be critically discussed. It has to be discussed if “full comprehension” is a feasible aim, even 
though there is a strong emphasis put on the information transmission in the counselling process of 
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the iterative feedback model. In the comment “Support for Full disclosure Up Front” (Holzer and 
Mastroleo 2015), I defended the position to support the information process prior to participation in 
research studies using WGS/WES procedures which aims for “full comprehension”. In the reply to 
the comment, Appelbaum et al. (2015) argue that “full comprehension” is an elusive endpoint in 
informed consent to research with regard to increasing amounts of information given to the 
participants which do not have apparent benefits. Thus, the realization of “full comprehension” 
might be out of reach. However, as stated in the theoretical framework, “full transmission of 
relevant information” and “full comprehension” is understood as the individuals’ comprehension of 
relevant information, i.e. what is being asked from them to understand. This systematically excludes 
an information overload Appelbaum et al. (2015) refer to.  
Moreover, Appelbaum et al. (2015) conclude from their assumption (full comprehension as an 
elusive endpoint) that informed consent cannot and should not necessarily aim for an ideal state of 
information. The authors mention that none of the discussed models (“Remodeling informed 
consent models in the context of research using WSG/WES and the disclosure of incidental 
findings”, Appelbaum et al. 2014) achieve the ideal state of information transmission and 
understanding (Appelbaum et al. 2014) which would justify their eligibility in the ethical debate. 
Nonetheless, it can be considered an “is-ought” fallacy when saying that the mere fact of an 
empirical observation (regarding therapeutic misconception) leads to the ethical justification for a 
model that does not aim for full comprehension. In contrast, the task how to improve the 
information transmission and the participants’ understanding should be subject to the ethical debate 
when designing an informed consent model.  
 
7.1.3 Post-trial counselling 
 
Since I emphasize in the proposed iterative feedback model a continuous counselling process, 
problems might arise with respect to counselling obligation years after the research project has been 
conducted. Here, we encounter a similar problem as post-trial access to beneficial interventions 
(Mastroleo 2014). Resource consumption over a long time period is one major concern, as well as 
participant’s availability due to address or name changes etc.. In the scope of WGS/WES research 
and the iterative feedback model, counsellors are supposed to continuously check new research 
results on genetic aberrations that could be of importance for the patient. Since genetic data is an 
un-exhaustible pool of data to answer different research questions, post-trial research and 
information is of high importance. To give a practical example, recommendations like the ACMG 
guidelines (Green et al. 2013) offering a selection of genes that should be revealed to the participant 
continuously change due to updates. Thus, post-trial counselling could be necessary for participants, 
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even a long time after the conduct of a study. 
Solving this problem of resource consumption and re-contacting participants may be the practical 
improvement of the communication process. Software could support counselors by e.g. automatic 
data matching between data banks and the participant’s individual data. Supportive tools should aim 
for a reduction of time and resource consuming procedures. 
 
7.1.4 Ancillary care obligations 
  
Another problem arising in the context of a WGS/WES studies concerns ancillary care obligations. 
Ancillary care is defined as health care that participants need which is not necessarily connected to 
safety or scientific validity of the research, injuries caused by the research study or to the fulfillment 
of moral demands promised in the informed consent process (Richardson and Belsky 2004:26). 
Especially in developing countries, ancillary care is of main importance due to the limited access to 
health care resources (Merritt 2011). In this work, there is no such focus on obligations because 
they are beyond the return of incidental findings and related to health care. If findings are revealed 
in the informed consent process, they can be of importance for the diagnosis of a disease. 
Therapeutic consequences, if there are treatment options or preventive measures, would have to be 
considered apart from the research study.  
However, the question that arises is very important in the WGS/WES research context and 
addresses further moral obligations of researchers and counsellors to provide adequate care for 
clinically significant findings that remain unrelated to the primary research question. In the context 
of WGS/WES research, such findings could be primary or incidental. Thus, there is need of a 
normative model addressing the question how to deal with ancillary care. Specifically, it should be 
answered (1) if there are ancillary care obligations (referring to a basis of principles) and (2) if yes, 
for which type of findings they are mandatory (content of moral obligations). (3) The lower and 
upper limits of the extension of the obligation should be non-arbitrarily located (cf. Merritt 2011).  
Furthermore, Merritt (2011) offers an interesting approach to show moral obligations of ancillary 
care, based on the general obligations (duties of justice and rescue) and special obligations 
(grounded in the researcher-participant relationship, including the concept of trust etc.). Applied to 
the case of WGS/WES research, it can be argued there are obligations to provide health care in case 
of findings that reveal genetic aberrations that are connected to clinically significant results that can 
potentially be treated. These obligations also have to involve the health care providers covering 
treatments or prevention.  
  
94 
Chapter 5. General conclusion  
 
In the course of this thesis, I have evaluated different informed consent models and their 
implementation into clinical practice which was guided by ethical principles and the reflection on 
specific characteristics of WGS/WES data. Drawing a conclusion from the analysis of the discussed 
informed consent models, there are important principles, values and concepts underlying these 
models, like cost-effectiveness, guaranty of autonomy, comprehension, and protection of 
participants/minimization of harms. The advantages and disadvantage of the consent models, as 
well as the most common values and ethical principles have been taken into account. 
This evaluation built the basis for the rationale to develop a new informed consent model in the 
context of research studies involving human subjects and using WGS/WES procedures, the iterative 
feedback model. I tried to design a model that is able to apply to the specific characteristics of 
WGS/WES by incorporating the ethical principles stated in the framework. However, there are still 
objections to the implementation of the iterative feedback model like in particular the problem of 
resource consumption. Nevertheless, the model offers many advantages, especially with regard to 
the approach to the informed consent requirement, namely voluntariness, full transmission of 
relevant information and full comprehension. 
 
In more detail, I justify a consent model for counselling prior to research participation and for the 
return of incidental findings after the onset of the research study. The communication between 
researchers and participants is linked by the counsellor (who explains the research study and reveals 
findings) and is embedded in a continuous counselling process. Furthermore, I have shown how the 
model could be implemented into practice on the basis of the current “rare diseases genomes project” 
in the United Kingdom.  
 
Summary  
 
After having outlined in Chapters 2 and 3 the biological and technical background of WGS/WES 
technologies, the technical characteristics of WGS/WES test procedures, the historical review of 
informed consent and its legal implementation, the general aim of the thesis consisted in the 
development of an informed consent model for the disclosure of incidental findings in the setting of 
clinical research studies involving human participants and using WGS/WES procedures.  
The scientific Chapter 2 and the historical and political perspective of Chapter 3 provided the 
background for a better understanding of ethical issues concerning the informed consent 
requirement adapted to WGS/WES technologies. Subsequently, Chapter 4 reconstructed the ethical 
95 
arguments for the design of the “iterative feedback model” which has been supported by the case of 
the “rare diseases genomes project”, a genome wide association study. Two strategies were applied 
to prove the hypothesis that the iterative feedback model fits best the ethical demands of consent 
taking for the disclosure of incidental findings in research studies using WGS/WES. On the one 
hand, the most important characteristics of WGS/WES data, namely heterogeneity, irreversibility, 
connectedness, and uncertainty were outlined and it has been discussed why an informed consent 
model must comprise a comprehensive and continuous (iterative) communication process to match 
these characteristics. On the other hand, an ethical framework for consent taking has been 
developed addressing ethical and pragmatic principles that are commonly found in the literature for 
informed consent. As an intermediate step, I analyzed and challenged common informed consent 
models for the disclosure of incidental findings in genomic research (Appelbaum et al. 2014) based 
on ethical principles. Subsequently, advantages and disadvantages of the models resulting from this 
evaluation have been outlined. The iterative feedback model was developed to avoid (most of the) 
disadvantages with a special focus on the evaluation of the principle of “autonomy” which should 
be granted by the newly introduced model.  In consequence, both strategies led us to the iterative 
feedback model, a model based on a traditional consent (communication prior to research 
participation) and on a dynamic consent (communication over time, involvement of the participant). 
Thus, the iterative model takes up the basic idea of the traditional and dynamic consent to 
communicate with the participants and to involve them actively and continuously in a 
communication process. However, differently to the dynamic consent, the iterative model offers a 
guided process of understanding to approach the complex issues arising in the context of research 
using WGS/WES procedures. While participants of the dynamic model communicate with 
researchers via an online platform, the iterative feedback model offers a specific and individual 
communication process assuring that all relevant information is communicated. 
 
Secondly, the aim has been to describe the iterative feedback model in more detail. “Counselling” 
was introduced as continuous communication process between counsellor and participant. The 
counsellor has been described as the link between researcher and participant, comparable to a 
personal mentor who goes through possible risks, benefits and outcomes of the research study and 
counsels on incidental findings that occur during the research conduct. Following Eckstein et al. 
(2014), a section was dedicated to elaborate the criteria, namely validity, value and volition (the 
“3V” framework) a research findings must meet in order to be revealed to the participant. Also 
important to mention is that the participant’s autonomously chosen preferences should be taken into 
consideration when seeking for and revealing incidental findings. This means that both, researcher 
and counselor are ethically required to respect participants and to respond to their questions, 
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concerns and wishes. Hence, the counselling process is supposed to contribute to the participant’s 
autonomy and to come up to the informed consent requirement comprising voluntariness, full 
transmission of relevant information and full understanding.  
 
Thirdly, possible objections to the iterative feedback model were stated addressing “resource 
management”, “therapeutic misconception”, “post-trial counselling” and “ancillary care 
obligations”. Regarding the first objection, resource management, I tried to outline that it may be 
difficult to estimate costs for the implementation of the iterative feedback model due to the different 
parameters that vary among all types of research studies using WGS/WES. Secondly, even if the 
implementation of the model is linked to high expenses, cost-effectiveness could be still granted 
through the superior benefits of the model (higher expenses are compensated by higher benefits). 
Also, it has been argued that supportive infrastructure for counselling services, as well as the 
financial contribution of research funders and sponsors could reduce the costs for the health care 
system.  
 
Furthermore, Appelbaum et al. (2015) states that participants are not able to understand relevant 
information for a fully autonomous choice. Responding to this objection, I argued that the iterative 
feedback model is an attempt to facilitate the understanding of participants. With regard to 
therapeutic misconception, this argument applies as well. When participants get confused with the 
distinction between the obligations of “researchers to participants” and of “physicians to patients” 
(assuming there are distinct obligations), an extended communication process is the only way to 
prevent such misunderstanding.  
 
Outlook and further research 
 
This dissertation provides an initial approach to the informed consent requirement in the particular 
setting of human health research studies using WGS/WES technologies. Not all aspects and 
challenges could be addressed in this thesis (cf. “Scope of the thesis”). The iterative feedback model 
implies post-trial counselling obligations over years. One major concern might be that re-contacting 
participants years after a study is conducted could add to a long and difficult process. However, 
online platforms could facilitate to stay in touch with the participants. Furthermore, it has been 
beyond the thesis’ aims to discuss ancillary care obligation in case of clinically actionable findings. 
Nevertheless, this is an important field in which research should be done. I considered it an ethical 
debate in itself to discuss the obligations of counsellors and researchers to provide adequate care for 
clinically significant findings that remain unrelated to the primary research question. Also, if there 
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is an obligation to provide care, it should be discussed which findings come into consideration for 
ancillary care obligations.  
 
Other topics that could not be addressed in the dissertation were “obligations towards third parties”, 
“confidentiality issues” and “storing, sharing and distribution of genomic data”. Hence, there are 
many important ethical issues related to new sequencing technologies and procedures that arise 
within each of the mentioned work fields.  
 
Moreover, it should be considered in future studies, how and which supportive tools, as software for 
data evaluation, online platforms or toolkits (e.g. the MRCT toolkit for the return of research 
results), could be helpful for the cost-effective implementation of the iterative feedback model.  
This is of importance in order to ensure a continuous counselling process over long time periods 
which should not excessively consume resources. Also, it would be helpful to do a systematic 
literature research on informed consent forms and the proposed recommendations on essential 
content and process in WGS/WES research which could be applied to the standards of counselling. 
Likewise, there has been work done for WGS studies in the clinical setting, extrapolating the most 
essential information that should be included in informed consent (Ayuso et al. 2013). 
 
In future work, there is still need to focus on the practical implementation of the iterative feedback 
model. The dissertation offers the theoretical and ethical framework for the informed consent model. 
Nevertheless, it would be of help to focus on empirical qualitative data to support the hypothesis 
that research using WGS/WES procedures needs an extended and iterative counselling process. 
Also, to address the objection of resource consumption, it could be focused on a very specific 
setting, respectively on a particular research study using WGS/WES procedures, to evaluate 
expenses and benefits resulting from the application of the iterative feedback model. 
 
In spite of the exploratory nature of this thesis, I have introduced the iterative feedback model with 
the firm aim to contribute tackling the ethical aspects of the fast development of new sequencing 
technologies which are rapidly becoming routine technologies. Especially when considering the 
tendency of the cost-reduction potential of sequencing technologies, WGS/WES tends to become an 
established practice in research and clinical care. In this regard, the model adapts the informed 
consent requirement to the technological trend. As history shows, the adaption and development of 
the informed consent requirement has been always linked to the misuse of participants or new 
technological and medical procedures. In the same way, the thesis adapts the informed consent 
process to the characteristics of WGS/WES in order to keep pace with the application possibilities 
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of WGS/WES.  
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